Autonomous capillary systems for life science research and medical diagnostics by Zimmermann, Martin

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
 
 
 
Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine 
kommerzielle Nutzung-Keine Bearbeitung 2.5 Schweiz“ lizenziert. Die vollständige Lizenz 
kann unter  
creativecommons.org/licences/by-nc-nd/2.5/ch 
eingesehen werden. 
Autonomous Capillary Systems for
Life Science Research and Medical
Diagnostics
inaugraldissertation
zur Erlangung der Würde eines Doktors der Philosophie
vorgelegt der
Philosophisch-Naturwissenschaftlichen Fakultät
der Universität Basel
von
Martin Zimmermann
aus Heitersheim, Deutschland
Basel, 2009
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf
Antrag von:
Prof. Dr. H.-J. Güntherodt (Fakultätsverantwortlicher)
Prof. Dr. N. F. de Rooij (Korreferent)
PD Dr. P. Hunziker (Experte)
Dr. E. Delamarche (Experte)
Basel, den 16. Oktober 2007
Prof. Dr. Hans-Peter Hauri, Dekan
Abstract
In autonomous capillary systems (CS) minute amounts of liquid are trans-
ported owing to capillary forces. Such CSs are appealing due to their portabil-
ity, flexibility, and the exceptional physical behavior of liquids in micrometer
sized microchannels, in particular, capillarity and short diffusion times. CSs
have shown to be a promising technology for miniaturized immunoassays in life
science research and diagnostics. Building on existing experimental demon-
strations of immunoassays in CSs, a theoretical model of such immunoassays
is implemented, tools and CSs for performing immunoassays are developed,
key functional elements of CSs such as capillary pumps and valves are ex-
plored experimentally, and a proof-of-concept of the ultimate goal of one-step
immunoassays are given in this work.
For the theoretical modeling of immunoassays in CSs a finite difference
algorithm is applied to delineate the role of the transport of analyte molecules
in the microchannel (convection and diffusion), the kinetics of binding between
the analyte and the capture antibodies, and the surface density of the capture
antibody on the assay. The model shows that assays can be greatly optimized
by varying the flow velocity of the solution of analyte in the microchannels.
The model also shows how much the analyte-antibody binding constant and
the surface density of the capture antibodies influence the performance of the
assay. We derive strategies to optimize assays toward maximal sensitivity,
minimal sample volume requirement or fast performance.
A method using evaporation for controlling the flow rate in CSs was devel-
oped for maximum flexibility for developing assays. The method allows to use
small CSs that initially are filled by capillary forces and then provide a well
defined area of the liquid-air interface from which liquid can evaporate. Tem-
perature and humidity are continuously measured and Peltier-elements are
used to adjust the temperatures in multiple areas of the CSs relative to the
iii
Abstract
dew-point. Thereby flow rates in the range from ∼ 1.2 nL s−1 to ∼ 30 pL s−1
could be achieved in the microchannels. This method was then used for
screening cells for surface receptors.
CSs, that do not need any peripherals for controlling flow rates become
even more appealing. We explored the filling behavior of such CSs having mi-
crochannels of various length and large capillary pumps. The capillary pumps
comprise microstructures of various sizes and shapes, which are spaced to en-
code certain capillary pressures. The spacing and shape of the microstructures
is also used to orient the filling front to obtain a reliable filling behavior and to
minimize the risk of entrapping air. We show how two capillary pumps having
different hydrodynamic properties can be connected to program a sequence of
slow and fast flow rates in CSs. Liquid filling CSs can hardly be stopped, but
in some cases it might be beneficial to do so. In a separate chapter we explore
how microstructures need to be designed to use capillary forces to stop, time,
or trigger liquids.
Besides well-defined flow rates in CSs accurately patterned capture anti-
bodies (cAbs) are key for performing high-sensitive surface immunoassays in
CSs. We present a method compatible with mass fabrication for patterning
cAbs in dense lines of up to 8 lines per millimeter. These cAbs are used
with CSs that are optimized for convenient handling, pipetting of solutions,
pumping of liquids such as human serum, and visualization of signals for
fluorescence immunoassays to detect c-reactive protein (CRP) with a sen-
sitivity of 0.9 ng mL−1 (7.8 pM) from 1 µL of CRP-spiked human serum,
within 11 minutes, with 4 pipetting steps, and a total volume of sample and
reagents of <1.5 µL.
CSs for diagnostic applications have different requirements than CSs that
are used as a research tool in life sciences, where a high flexibility and
performance primes over the ease of use and portability of the CSs. We
give a proof-of-concept for one-step immunoassays based on CSs which we
think can be the base for developing portable diagnostics for point-of-care
applications. All reagents are preloaded in the CSs. A sample loaded
in the CSs redissolves and reconstitutes the detection antibodies (dAbs),
analyte-dAb-complexes are formed and detected downstream in the CSs. A
user only needs to load a sample and measure the result using a fluorescence
iv
microscope or scanner. C-reactive protein was detected in human serum at
clinical concentrations within 10 minutes and using only 2 µL of sample.
v
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1. Introduction
Medical diagnostics is the process of identifying a medical condition or dis-
ease by its signs, symptoms, and from the results of various diagnostic proce-
dures. Numerous medical tests are commonly performed with patients having
abnormal symptoms, such as measuring blood pressure and pulse rate, ap-
plying medical imaging methods (e.g. ultra sound imaging), electrical mea-
surements (e.g. electrocardiogram) or analyzing body liquids (blood, urine,
saliva, cerebrospinal liquid). A reliable diagnosis is a challenging and com-
plex procedure that typically requires medical professionals to conduct sev-
eral tests and interpret their results. In some cases, patients perform tests on
their own after they have been taught how to interpret the results, such as
diabetes patients [1], or if tests are simple to use and self-explaining, such as
pregnancy tests [2].
A number of immunoassay tests [3], which are performed to determine an-
tibody and antigen concentrations in body liquids, require skilled operators
or complex robotic analyzers to pipette, time and repeat several steps while
performing the test. In the case of acute diseases, such as acute myocar-
dial syndrome, fast diagnostic results within a few minutes are essential to
start proper treatment early for the patient’s benefit. This thesis explores
concepts for fast and sensitive immunoassays using capillary systems (CS) in
which liquids are moved owing to capillary forces. Such CSs might help im-
prove medical treatments by providing high-sensitive and quantitative results
within a short time, with ease-of-use and economy of cost. CSs might also
enable applications for life science research, that require immunoassays which
can be performed with ultra small sample volumes.
1
1. Introduction
1.1. Trends in Medical Immuno-Diagnostics
Modern immunoassays date back to 1959 when the principle was first de-
scribed using a radioimmunoassay for insulin [4]. Since then, immunoassays
have proved to be one of the most productive technological contributions to
medicine and fundamental life science research. Immunoassays have been
implemented on various platforms. State-of-the-art clinical random-access
analyzers perform bead based immunoassays in tubes. Random-access ana-
lyzers are fully automated, allow samples to be loaded at any time, and have
a throughput of >200 samples per hour [3]. These analyzers are operated in
centralized laboratories. Immunoassays in life science research are performed
in microtiter plates having up to 1536 individual wells which enable a higher
throughput than clinical analyzers. Robotic liquid handlers fill and aspirate
liquids from the wells and tubes according to the protocol of the immunoassay.
The growing demand of fast, accurate, economical and automated analyt-
ical systems has emerged the idea of micro total analysis system (µTAS) or
lab-on-a-chip (LOC) [5, 6] in the 1990s. The vision of a miniaturized clinical
analyzer in the palm of one’s hand still persists. LOC benefit from the ex-
ceptional physics and behavior of liquids in micrometer sized capillaries and
uses these phenomena to process, mix, and capture reagents. Immunoassays
in micrometer sized dimensions enable rapid analysis due to short diffusion
distances, and require little analyte volumes which also saves precious and
expensive reagents. Efficient mass transport and rinsing at the microscale
might also ease the simplification and integration of assay steps, such as sam-
ple preparation and analysis of results. The small size facilitates the fab-
rication of handheld analyzers that are suitable for performing urgent test
at the point-of-care.
This vision has evolved into the first devices that perform a few critical
measurements on-chip. The implemented concept of a portable blood gas an-
alyzer [7] exemplifies the performance of such systems. A single use cartridge,
comprising a membrane for cell filtration and a sensor is loaded with a drop
of blood and inserted into a handheld analyzer. After a few minutes, results
can be read on the screen of the analyzer and transferred to the laboratory
information system. Similar devices can be used to perform immunoassays
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for cardiac markers [8, 9]. A growing number of companies are active in the
production and commercialization of a large variety of miniaturized and ef-
fective analytical devices [10], but most of the LOC devices are still far from
small due to bulky peripherals [11], or are not yet ultimately fast.
The trend to miniaturized analytical systems is supported by existing fab-
rication techniques originally applied in the field of microelectronics. Pho-
tolithography and 3-dimensional structured silicon wafers are used for mi-
crofluidics. We will now discuss the physical properties from which miniatur-
ized analytical systems might benefit.
1.2. Miniaturization Effects
Miniaturization will obviously scale down volumes, but might also change
the relative magnitude between forces of different origin. Effects of marginal
importance at the macro-scale might dominate at the micro-scale [12]. Figure
1.1 shows a cube having an edge length a. Shrinking a increases the surface-
to-volume ratio
A
V
∝ a
2
a3
= 1
a
(1.1)
of the surface area A and the volume V of the cube significantly. The flow
becomes laminar at length scales of millimeters depending on the flow velocity
and the viscosity of the liquid. In such small volumes mixing of reagents is
provided by convective laminar flow and by diffusion instead of turbulences
such as in large volumes [13]. Diffusion is comparably fast at the micrometer
scale: A medium sized protein diffuses ∼10 µm within a second compared to
2.7 hours for a distance of 1 mm.
While scaling down the volume of an analyte, its concentration needs to
be considered. The absolute number of analyte molecules might statistically
get below one analyte molecule per sample if low concentrations of analyte
are anticipated and too small sample volumes are used. For example, 1 µL of
analyte having a concentration of 1 pg mL−1 (10 fM for a protein of the size
100 kDa) contains ∼6000 individual proteins, whereas in 1 nL and 1 pL of the
same concentration only 6 and 0.006 proteins are left, respectively.
However, if the area in which the concentration is measured, is reduced
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Figure 1.1. Scaling of surface and volumes.
as well, less molecules might be required in order to generate a significant
signal. In our micromosaic immunoassays [14] the area in which proteins
are captured and quantified using fluorescence techniques can be as small as
30 × 30 µm2. If we assume the footprint of one capture site being the size
of 150 nm2 [15, 16] and 10 % active binding sites properly oriented towards
the liquids phase [3], 600000 bound and labeled proteins would result in a
maximum signal. Depending on the intensity of the fluorophores and the
sensitivity of the instrument ∼450 proteins should still be detectable [17].
In the remainder of this section we will discuss constraints which are par-
ticularly important for developing and using microfluidic capillary systems.
1.2.1. Surface Tension
Surface tension originates from intramolecular forces and describes the in-
teraction between a liquid and its own gas. Surface tension can shape the
surface of microvolumes of liquid, Fig. 1.2. Young’s equation relates different
interfacial energies σij of vapor-solid (vs), liquid-solid (ls), and vapor-liquid
4
1.2. Miniaturization Effects
Figure 1.2. Shape of a drop of liquid on solid surfaces in a gas atmosphere. (a) Non-
wettable surfaces having a contact angle α > 90◦ are hydrophobic. (b, c) Wettable or
hydrophilic surfaces, respectively, have contact angles α < 90◦. The surfaces in (a) and (b)
are partially wetted and fully wetted in (c) α = 0◦.
(vl) interfaces via the equilibrium contact angle α of the liquid to the surface:
σvs−σls = σvl cosα. The droplet of liquid in Fig. 1.2a has a poor wettablility
on the surface and forms a contact angle α > 90◦ at the solid-liquid-vapor
contact line. This surface is partially non-wettable with this particular liquid.
In contrast, the surface in Fig. 1.2b and c having a contact angle α < 90◦ and
α = 0 is partially and fully wettable, respectively. A surface is fully wetted
when the gain in free energy at the solid-liquid interface is larger than the
surface free energy of the liquid. In the case of water a wettable surface is
commonly defined as hydrophilic, a non-wettable one as hydrophobic. The
difference between the contact angles αa and αr of an advancing and reced-
ing contact line respectively, is called contact angle hysteresis. Liquids on
rough or chemically inhomogenous surfaces tend to have larger contact angle
hysteresis than the same liquids on flat and chemically homogenous surfaces.
The contact angle is often measured to evaluate the cleanliness of a surface
[18, 19]. Organic contamination increases the contact angle which results in
poor wettability. CS are wettable on their inner surfaces in order to generate
a negative capillary pressure and might have hydrophobic areas in selected
regions to prevent contamination or to time liquids [20, 21].
1.2.2. Capillary Flow
In microvolumes forces related to surface tension often dominate gravity, in-
ertia or friction. The conversion of surface tension into capillary pressure is
described by the Young-Laplace equation [22, 23]. The capillary pressure
Pc = −σ
(cosαb + cosαt
d
+ cosαl + cosαr
w
)
(1.2)
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Figure 1.3. Capillary pressure in capillaries of different diameter. The inner surface of the
capillaries are hydrophilic (a, c) and hydrophobic (b).
for rectangular capillaries of width w and depth d is a function of the surface
tension σ and the contact angles αi with the indices b, t, l, r referring to bottom,
top, left and right walls, respectively.
Capillaries having hydrophilic surfaces which are partially dipped into a
water bath imbibe water, see Fig. 1.3. Thus water levels in hydrophilic
capillaries are higher than the water level of the bath. In contrast, the level in
a hydrophobic capillary does not exceed the level of the bath. The exact height
of the water level inside the capillaries depends on their diameter. Smaller
capillaries have larger absolute capillary pressure.
The Reynolds number Re quantifies the ratio of inertial to viscous forces
and is used to distinguish between laminar and turbulent flow regimes. It is
calculated as [24]
Re = ρvL
η
, (1.3)
where ρ is the density, η the dynamic viscosity, and v the mean velocity of the
liquid, and L the characteristic length of the flow path. For circular capillaries
L equals the capillary diameter and for non-circular cross-section the hydraulic
diameter Dh = 4AU where A is the cross-section and U the wetted perimeter
of the cross-section is used. A flow is laminar for Re < 2300. In microfluidics
mostly Re < 1 is valid.
The hydrodynamics of a flow of liquid is described by the Navier-Stokes
equation. In the case of pressure-driven steady laminar flow in a capillary,
the solution is known as the law of Hagen-Poiseuille which describes the
6
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Figure 1.4. Flow and concentration profile in microcapillaries. (a) Characteristic parabolic
flow profile in a microcapillary. (b) Effect of the parabolic flow profile on the concentration
profile. A plug of liquid having a concentration C0 which is flowing in-between liquid plugs
having the concentration C1 < C0 is diluted.
characteristic flow velocity
v(r) = ∆P4ηl
(
R2 − r2
)
, (1.4)
where r is the distance from the center, R the radius, l the length, and ∆P
the difference of the pressure between the inlet and outlet of a capillary. The
flow velocity is maximum in the center, and zero at the walls of a capil-
lary. This results in smearing of an analyte concentration C0 in a plug of
liquid which is placed in-between plugs of the same liquid having an ana-
lyte concentration C1, Fig. 1.4. This effect might be useful for mixing of
reagents, but also prevents two liquids from flowing sequentially in a capillary
without being diluted.
The flow rate I in a capillary can be expressed as
I = 1
η
∆P
Rf
. (1.5)
The friction factor Rf times the viscosity η is the hydraulic resistance of
the capillary. For a capillary that fills only owing to capillary forces ∆P
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corresponds to the capillary pressure. The friction factor is calculated from
the geometry of the round capillary
Rf5 =
(
piR4
8l
)−1
=
(
1
8
AR2h
l
)−1
, (1.6)
where A is the cross section of the capillary and Rh the hydraulic radius. The
friction factor increases while filling the capillary with l corresponding to the
filled length.
Capillaries which are etched into silicon using dry-etching have a rectangular
cross-section. Such capillaries are termed “microchannels” in this work. The
friction factor of microchannels can be derived from a Taylor series and be
written as a first-order approximation with no more than 10 % deviation from
the original value [25]
Rf0 =
(
1
12
(
1 + 5a6b
)
AR2h
l
)−1
, (1.7)
with width a and depth b, a < b, of the microchannel.
1.2.3. Diffusion
Brownian motion [26], thermally induced random motion of molecules, results
in diffusion and in mass transfer in the presence of concentration gradients.
The flux of diffusion is described by Fick’s law
ji = −Di∇Ci, (1.8)
whereDi is the diffusion coefficient, and∇Ci the concentration gradient of the
species i. The Stokes-Einstein-relation D = kT6piηRhydro is applied to calculate
the diffusion coefficient of globular proteins, with the Boltzmann constant k,
the temperature T , and the hydrodynamic radius Rhydro [27]. The diffusion
constant D of proteins in aqueous solution typically ranges from ∼ 10−7 −
10−5 cm2 s−1 depending on their size. The average time tD for diffusing a
distance d is given as
tD =
d2
2Di
. (1.9)
A protein having the size of 17 kDa has a diffusion coefficient of 10−6 cm2 s−1.
It needs 0.05 s for a diffusion distance of 10 µm. Thus reactions in fluidic
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microchannels benefit from a short diffusion time of the reactants. In combi-
nation with the convective laminar flow described above, reaction rates can
be well controlled by supplying more or less reactants with fast or slow flow
rates, respectively. Macroscopic reactions can not reach a similar degree of
accuracy in controlling a reaction due to the time lag caused by slow diffusion
rates and less precise turbulent mixing.
1.3. Principles of Immunoassays
Immunoassays derive their unique characteristics from important properties of
antibodies: (i) their ability to bind to an extremely wide range of biomolecules,
cells and viruses, (ii) their exceptional specificity for the substance to which
each antibody binds and (iii) the strength of the binding between antibody and
its target [3]. A widely used variant of immunoassays which forms multiple
layers of proteins on a surface is known as sandwich immunoassays. Anti-
bodies, that were immobilized on a surface (capture antibodies, cAb) bind
(capture) analytes from solution. Labeled secondary antibodies (detection
antibodies, dAb) detect bound analytes. Detection Abs are specific to other
binding sites on antigens than cAbs and have radioactive isotopes, enzymes,
or fluorescent molecules, as labels, which can be measured. The obtained
signal is directly proportional to the concentration of analyte. Typically each
species is applied sequentially to the surface and a number of rinsing steps
are performed between different steps and before measuring the final result
on the surface.
The reaction between antibody and antigen is described by the Law of Mass
Action [3]
[Ag] + [Ab]
kon
GGGGGGBF G
koff
[Ag − Ab] (1.10)
where [Ag] and [Ab] are the concentration of antigen and antibody, respec-
tively, [Ag − Ab] the concentration of antigen-antibody-complex, kon the as-
sociation rate constant, and koff the dissociation rate constant. The ratio of
the two rate constants give the equilibrium constant K = kon
koff
, which is also
known as the affinity constant.
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1.4. Objectives and Structure of this Thesis
This thesis is structured in cumulative chapters which have been published as
journal papers. We will give a short outline of the objectives of the chapters
and thesis in general.
We are in particular interested in developing tools and methods for fast and
sensitive immunoassays which ultimately could lead to portable and easy to
use devices operated outside of centralized laboratories or even in ambulances
(point-of-care). Such immunoassay tests are required to have no bulky pe-
ripherals, ideally be as accurate as clinical laboratory test, and convenient to
use. Ideally, only a body liquid would be required to be loaded on a certain
region of the device.
In order to design and develop optimal immunoassays and capillary systems
a precise understanding of the kinetics of immunoassays in capillary systems
is required. The definition of an optimal assay depends on the application: it
might be fast, consume ultimately minute volumes, or have a wide range of
measurable analyte concentrations. We have developed and implemented a
model, which allows to simulate concentration profiles in microchannels and
the kinetics of immunoassays performed in such microchannels. The most
important parameters leading to optimal assays are comprehensively discussed
in Chapter 2.
One of the key challenges is to precisely, reliably and economically control
the flow of minute amounts of liquids in microchannels. Capillary systems
have the flow rate preprogrammed at the time of fabrication and therefore
have limited flexibility. However, while developing assays, flexible systems are
desirable in order to easily tune a flow rate depending on the characteristics
of the assay. We have set up a platform that allows the user to program a
flow rate in microchannels at the time of use. The platform is described in
Chapter 3. It is based on the evaporation from a certain region of the capillary
system and controls the temperature in different zones of the capillary system
relative to the ambient dew point.
In Chapter 4 the platform described in Chapter 3 is used to develop a cell
assay. Living cells are flown through the capillary system and screened for
specific proteins on their cell membrane. This assay benefits in particular from
10
1.4. Objectives and Structure of this Thesis
the ability to control the temperature in the capillary systems. In addition,
the metabolism of living cells is sensitive to temperature and the kinetics of
proteins and cells are optimal at 37 ◦C.
The challenge of controlling the flow of minute amounts of liquid in capillary
systems having no peripherals is addressed again in Chapter 5. The compo-
nents of capillary systems having the highest impact on the flow behavior of
liquid in CSs are discussed. Flow resistors are used to tune the flow rate in
microchannels and most importantly, large capillary pumps having a reliable
filling behavior are developed.
The knowledge gained from designing capillary systems in which liquids
move due to capillary forces resulted in the fabrication of chips having six
independent capillary systems and suited to displace up to 2 µL of sample
volume. In previous work, the method used for immobilizing capture anti-
bodies to perform micromosaic immunoassays required a second microfluidic
chip. This method is effective and accurate but requires a microfluidic chip
to be cleaned and coated with a hydrophilic monolayer before each use. The
handling overhead of such a method is significant and lead to the design of a
simplified method that might also be compatible with mass-fabrication. Thus
the protocol to perform a CRP-immunoassay using CSs and stencils is dis-
cussed in Chapter 6.
Novel microfluidic capillary systems for one-step immunoassays that require
only the analyte to be loaded on the CS are investigated in Chapter 7. A
method was developed to predeposit the detection antibodies in a dried form
in the CS and their reconstitution was investigated.
A liquid that is flowing in a CS can hardly be stopped before the CS is filled
or all liquid has been imbibed. However, one could think of circumstances that
would benefit form stopping a liquid for a certain time, such as timing, meter-
ing, and triggering liquids. Hydrophobic patches in microchannel could stop
a liquid but patterning those patches needs additional processing steps. A
method using specifically shaped microstructures that stop liquid is investi-
gated in Chapter 8.
Finally, Chapter 9 concludes on the potential of CSs based on the work
presented in this thesis.
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2. Modeling and Optimization of
High-sensitivity, Low-volume
Microfluidic-based Surface
Immunoassays
Microfluidics are emerging as a promising technology for miniaturizing biolog-
ical assays for applications in diagnostics and research in life sciences because
they enable the parallel analysis of multiple analytes with economy of sam-
ples and in short time. We have previously developed microfluidic networks
for surface immunoassays where antibodies that are immobilized on one wall
of a microchannel capture analytes flowing in the microchannel. This tech-
nology is capable of detecting analytes with picomolar sensitivity and from
sub-microliter volume of sample within 45 min. This chapter1 presents the
theoretical modeling of these immunoassays where a finite difference algo-
rithm is applied to delineate the role of the transport of analyte molecules
in the microchannel (convection and diffusion), the kinetics of binding be-
tween the analyte and the capture antibodies, and the surface density of the
capture antibody on the assay. The model shows that assays can be greatly
optimized by varying the flow velocity of the solution of analyte in the mi-
crochannels. The model also shows how much the analyte-antibody binding
constant and the surface density of the capture antibodies influence the per-
formance of the assay. We then derive strategies to optimize assays toward
maximal sensitivity, minimal sample volume requirement or fast performance,
1M. Zimmermann, E. Delamarche, M. Wolf and P. Hunziker, Modeling and Optimiza-
tion of High-Sensitivity, Low-Volume Microfluidic-Based Surface Immunoassays, first
published in Biomedical Microdevices 7:2, 99–110, 2005.
13
2. Modeling and Optimization of Microfluidic-based Immunoassays
which we think will allow further development of microfluidic networks for im-
munoassay applications.
2.1. Introduction
Microfluidics and biochips, which are derived from microfabrication tech-
niques, are emerging as powerful bioanalytical platforms [28, 29]. Microfluidics
in particular, have the potential to detect multiple analytes in a small vol-
ume of sample and can integrate multiple functionalities for the processing
of samples and the generation and acquisition of signals [30]. For these rea-
sons, microfluidic devices are developed and used for detecting disease markers
and screening drug candidates as well as for antibody characterization [31].
Different methods can be employed to move liquids in microfluidics, such as
pressure-driven flow, electro-osmosis, or acceleration. Ideal microfluidics are
simple to utilize, reliable, fast, sensitive, versatile, and cheap. One of the
simplest approaches for producing flow in capillaries is to use capillary forces.
Capillary-driven flow requires no peripheral equipment, and this concept is
used for portable immunodiagnostic tests [32].
We are interested in developing capillary-driven microfluidic chips for diag-
nostic and bioanalytical applications in which fluorescence surface immunoas-
says are performed in the microchannels of the chip, samples of 1 µL in volume
or less are used, multiple analytes are detected, and sensitivities down to 1 pM
concentration of analytes can be achieved. An important step in developing
these devices was to employ a hydrophobic elastomeric substrate for the assay
and covering the elastomer with a Si microfabricated element having a plural-
ity of microchannels [14]. The assay takes place on the areas of the elastomer
that are exposed to the microchannels. Each microchannel starts with a load-
ing pad and ends with a capillary pump [33]. The capillary pressure along
the flow path is encoded to secure the unidirectional filling of the liquid from
the loading pad to the capillary pump. Therefore, assays are done by loading
the necessary reagents (e.g. capture antibody and detection antibody) and
samples in the correct sequence in each loading pad. The assay conditions
in adjacent microchannels can be varied independently because the elastomer
seals the microchannels efficiently. This concept was recently exemplified by
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detecting tissue necrosis factor-α (TNF-α) in 0.6 µL volume of cell culture
supernatant with 1 pM sensitivity, and up to 170 test sites were made on a
1 mm2 area of the elastomer [34]. This concept was also qualitatively applied
to detect disease markers such as C-reactive protein (CRP) [35]. Because clin-
ically relevant analyte concentrations are often spread over a wide range from
micromolar to picomolar concentrations, optimizing the microfluidic devices
in terms of covering a large dynamic range for the measurements is important.
At the same time, a microfluidic device should also be suited to handle very
small concentrations and if possible minute volumes of analyte.
We are interested in examining these previous results analytically to iden-
tify the predominant assay parameters and to derive optimization strategies
for performing assays with such microfluidics for having optimal sensitivity,
minimal sample requirement, or fastest possible times to results.
Like other computational studies on the kinetics of antigen binding in mi-
crochannels [36, 37, 38, 39, 40], our computational model of fluid dynamics
includes convection, diffusion and receptor-ligand kinetics [41, 42] of capillary-
flow-driven microfluidic channels and was implemented using a finite difference
approach [43]. Thereby, we solved the steady-state uncompressed Navier-
Stokes equation, combined with a convection-diffusion model and a fluid-wall
interaction model which we describe below.
2.2. Methods
2.2.1. Microfluidic networks used in the analyses
Our model is implemented to describe the binding of an antigen to a surface-
immobilized capture antibody in a microchannel, Fig. 2.1, and is based on
the geometrical characteristics of microfluidic networks that we used previ-
ously [34]. The microfluidic networks had several independent microchannels,
and we therefore only need to consider one microchannel. Each microfluidic
channel is 20 µm deep, 30 µm wide and 1 mm long. In typical experiments,
the capture antibodies are present in the second half of the channel, and the
analytes cannot be lost by sticking to the walls elsewhere than at the capture
sites because the walls are treated to be protein-repellent [44]. The capture
15
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Figure 2.1. Configuration of a surface immunoassay in a microfluidic channel. The liquid
enters the channel at the inlet on the left-hand side and flows through the channel under
laminar conditions with a parabolic flow profile. The flowing analyte solution contains
molecules which are transported in the channel. The molecules are allowed to diffuse
perpendicularly to the flow direction and can be captured by the capture antibodies. Wall
elements not covered with capture antibodies are protected against unspecific binding,
which in the simulation is regarded as perfect.
area is covered by individual capture antibody molecules with a given surface
density. We define the “feature area” as the total capture area divided by the
number of active capture antibodies. If all capture antibodies were properly
oriented and able to bind two antigens each, the feature area would be equal
to half the footprint of a capture antibody. In practice, only a fraction of
the capture antibodies might be functional and we will therefore explore the
influence of the feature area on the assays.
The analyte solution flows into the microchannel at constant flow velocity
and flow rate. The flow of an aqueous solution inside a small channel is
typically laminar (Reynolds number  1) and has a parabolic flow profile.
The analyte molecules are transported by convection along the flow direction
and in addition are free to diffuse. Each time an analyte molecule reaches
a capture site, a standard ligand-receptor binding model is applied to define
whether capture occurs. Both the association and dissociation events are
modeled. The binding kinetics as well as the convection-diffusion model are
described in more detail in the next section.
In the model, we define the analyte exploitation as the ratio between
the number of captured analyte molecules and the total number of analyte
molecules that were present in a given volume of sample that passed over
the capture zone. An assay where all analyte molecules would flow in the mi-
crochannel without being captured would have an analyte exploitation of zero
16
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and would generate no signal. Inversely, an ideal assay would have an analyte
exploitation of one. The available volume of analyte solution is considered to
be unlimited except when the simulation is used to study the exploitation of
analyte.
2.2.2. Models
The flow of a liquid in a region over time t is characterized by a velocity vector
field ~u, a pressure p and a density ρ. For laminar, incompressible and viscous
fluids the density is constant. The flow is described by the Navier-Stokes
partial differential equation system
∂
∂t
~u+ (~u · grad) ~u+ grad p = 1
Re
∆~u+ ~g (2.1)
div ~u = 0 (2.2)
in dimensionless form with the Reynolds number Re and external forces ~g.
External forces such as gravity can be neglected in such miniaturized systems.
For Re  2100, flow is considered to be laminar and has a characteristic
parabolic flow profile with zero flow velocity at the channel walls and peak
flow velocity in the channel center. Here, Re is ∼ 0.07 for the maximum flow
rates considered.
The bulk concentration C of a solute in a given solution is described by the
Convection-Diffusion equation of the form
∂C
∂t
+ ~u · grad C = D∆C + Θ (t, x, y, C) (2.3)
with a diffusion coefficient D, a source term Θ and the identical velocity
vector field ~u given in Eqn. 2.1. We have applied the Stokes-Einstein-relation
D = kT6piηRh , with the hydrodynamic radius Rh, the analyte viscosity η and the
Boltzmann constant k to estimate the diffusion coefficient D of the analyte
molecule to D = 10−6 cm2s−1 which we used for all further calculations and
which corresponds to the literature [45] where comparable values for small
molecules such as TNF-α are reported. The analyte viscosity was set to a
high plasma viscosity [46] of 2 mPa s.
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The association and the dissociation from the capture site are described
by the rate coefficients k, the analyte concentration C and the density of
free binding sites (Θmax −Θt) on the surface, using an ordinary differential
equation of the form,
dΘt
dt
= kon C (Θmax −Θt)− koff Θt (2.4)
for monovalent receptors and ligands. kon is the rate constant for associa-
tion, koff is the rate constant for dissociation, C is the concentration of free
molecules in the fluid, Θt is the surface density at time t. Θmax is the max-
imum surface density of molecules calculated from the feature area of the
individual capture molecules and is assumed to be constant over time. In this
simulation we generally used 106 M−1 s−1 for kon and 10−3 s−1 for koff [47],
but in some case these constants were modified.
The set of Eqn. 2.1 - 2.4 is used to implement the model describing the
capture of an analyte by a surface-immobilized capture site in a microfluidic
channel. This model uses the finite difference approach to calculate the influ-
ences of the key parameters on the capture of analyte. The model is detailed
in Appendix A, Section A.1, and validated in Section A.2 by comparing re-
sults from the simulation with analytical results when the equations could
be solved analytically. Eqn. 2.4 in particular can be solved analytically for a
constant analyte concentration:
Θt =
kon Θmax C
kon C + koff
(
1− e−(kon C+koff) t
)
. (2.5)
The maximum binding density Θˆbound of analyte on the capture area de-
pends only on the analyte concentration and the binding constants kon and
koff which are also known as the equilibrium constant K:
Θˆbound =
kon Θmax C
kon C + koff
(2.6)
K = kon
koff
(2.7)
[K] = [s
−1M−1]
[s−1] .
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2.3. Results
The combination of Eqn. 2.1 – 2.4 allows the study of the influence of flow
rate, analyte bulk concentration, capture-site surface density and binding-
rate coefficients on the binding kinetics. Experimentally, captured analytes
might be detected directly using surface-sensitive techniques or by binding
them with fluorescently-labeled detection antibodies. We do not need to take
the binding between captured analytes and detection antibodies into account
because this step is generally not limiting in immunoassays: a high concen-
tration of detection antibodies can be used to ensure fast completion of this
binding reaction, for example. First, we need to determine when the capture
reaction is reaction-limited or transport-limited.
2.3.1. Reaction-limited versus transport-limited kinetics of
capture
One of the key parameters that determine whether the kinetics of capture of
analyte is reaction-limited or transport-limited is the velocity of the analyte
solution in the microchannel. The capture of the analyte is reaction-limited if
the number of molecules binding to the capture site per unit of time remains
similar for different flow velocities. In contrast, the capture of the analyte
is transport-limited if the number of analyte molecules binding per unit of
time is sensitive to the flow velocity of the sample in the microchannel. The
analyte exploitation is represented in Fig. 2.2 as a function of the flow velocity.
It increases with decreasing flow velocity because insufficient mass transport
increases the reaction time for capture. For velocities above 0.5 mm s−1,
corresponding to flow rates higher than 18 nL min−1 for the channels used
in previous experiments, a system with a binding constant K of 109 M−1
and a feature area of 1500 nm2 is reaction-limited: the residency time of the
analytes on the capture area is short and the analyte exploitation therefore is
small (∼ 5 %). At lower flow rates, the analyte exploitation increases but the
binding reaction becomes transport-limited because lower volumes of analyte
solution are available at the capture area per unit of time and thus fewer
molecules have a chance to be captured per unit of time. A flow velocity
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Figure 2.2. Calculated mean analyte exploitation as a function of the flow velocity in the
first five minutes of the incubation time with 1 pM analyte concentration. Adjusting the
flow velocity (and flow rate) affects the exploitation of the analyte molecules in a sample
and is therefore useful to minimize the absolute volume of analyte required for saturation
of the capture sites. The line is provided as a guide to the eye. A binding constant of
109 M−1, analyte concentration of 1 pM and a feature area of 1500 nm2 were selected here.
of 0.7 mm s−1 was used in previous work [34], and we suggest that these
experiments were performed in the reaction-limited regime. We consider this
flow velocity as well as lower flow velocities in the remainder of the paper
to encompass the different regimes. We specifically choose a flow velocity of
0.07 mm s−1, where transport limitation already occurs, and a flow velocity of
0.007 mm s−1, where the capture according to Fig. 2.2 falls in the transport-
limited regime. In this latter case, longer incubation times are necessary to
reach an equivalent signal intensity to the reaction-limited case. In contrast
to the transport-limited case, the molecules in the sample volume are used
more efficiently.
We investigate the influence of the flow velocity and the feature area on the
number of analytes captured per unit area, Fig. 2.3. Capture antibodies that
are passively adsorbed on a hydrophobic surface have a footprint of ∼ 150 nm2
[15, 16] and it has been suggested that for this mode of deposition ∼ 10 %
of the antibodies might be correctly oriented and preserved for capturing one
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Figure 2.3. Binding of analytes in solution to surface-immobilized antibodies as a function
of time and for a concentration of analyte of 1 nM (a, b) and 1 pM (c, d), and for a
feature area of 1500 nm2 (a, c) and 150 nm2 (b, d). This binding reaction corresponds to
the capture step of a surface immunoassay and takes place in a microchannel as shown in
Fig. 2.1. The binding reaction is more sensitive to mass transport limitations for the smaller
feature areas (b and d) as well as for lower analyte concentrations (c and d). A hypothetical
analyte-antibody binding constant of K = 109 M−1 was chosen for these analyzes.
antigen from solution [3], which here would correspond to a feature area of
1500 nm2. Using oriented antibodies and advanced surface-immobilization
strategies, the feature area can be decreased. We consider for this reason
a scenario where each capture antibody has a chance to bind one antigen
(feature area of 150 nm2). The model developed here can also be applied to
situations with very different feature areas, microchannel dimensions, binding
constants, and flow velocities.
Figure 2.3 shows how many analyte molecules are captured per unit area
as a function of time for feature areas of 1500 nm2 and 150 nm2, various flow
rates, and analyte concentrations of 1 nM and 1 pM. We selected 1 nM for the
analyte concentration because it corresponds to immunoassays that are rela-
tively sensitive and used for many clinical applications [3]. A concentration of
1 pM represents a practical limit in sensitivity for immunoassays and we want
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to use the model developed here to optimize assays done using microfluidics
for this analyte concentration. Figure 2.3a and 2.3b show that, as expected,
the maximum surface density of captured analyte is inversely proportional to
the feature area, but also that the kinetics of capture is affected by the feature
area. For a larger feature area (1500 nm2), it is less important to keep the
flow velocity high enough to repopulate the microchannel with new analytes
because the assay is reaction-limited. This explains the similar outcomes of
assays done using flow velocities of 0.7 and 0.07 mm s−1. The binding reac-
tion becomes transport-limited for a flow velocity of 0.007 mm s−1, as visible
in Fig. 2.3a. The graphs in Fig. 2.3b indicate that capture zones having a
smaller feature area exploit the solution from analyte faster than those with
a larger feature area. As a consequence, the flow rate has a larger influence
on the binding kinetics in the case of smaller feature areas.
The surface density of captured analytes decreases dramatically when an-
alytes are at 1 pM concentration, Fig. 2.3c and 2.3d, which is dictated by
the equilibrium constant K. The binding reaction is slower than at 1 nM in
all cases, and the flow velocity as well as the feature area affect the capture
reaction in a similar way as at the higher concentration.
2.3.2. Linear binding saturation curves at very low flow
velocities
Biological assays that need a long time to reach equilibrium might have to be
stopped early for convenience. The graphs in Fig. 2.3a and 2.3b show that
saturation in binding is nearly reached within 1000 s for a flow velocity of
0.7 mm s−1. The binding reactions for lower flow velocities are much slower
and show a linear behavior. Although assays done under these conditions
yield small signals, they can be conveniently stopped at any point in time,
because uncertainties on the incubation time give small errors on the signal.
The model predicts that an assay with 1500 nm2 feature area, 1 nM analyte
concentration, and 0.007 mm s−1 flow velocity has a relative error of only
± 4% when the incubation time is 300 ± 15 s. Interestingly, such an assay
leads to having 52 ± 2 captured antigen per µm2, which after the binding
of detection antibodies should correspond to a signal well above the limit
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of detection of conventional fluorescence scanners. The model suggests that
assays done with a 1 nM analyte concentration and different conditions have
a similar relative error when they are stopped after an incubation time of
300 ± 15 s. The graphs in Fig. 2.3c and 2.3d reveal a similar linear evolution
of the signal with time for a 1 pM analyte concentration. However, stopping
the assay after an arbitrarily short time for this lower analyte concentration is
unlikely to be practical because of the much lower surface density of captured
analyte after 300 s (5 min). Long incubation times are therefore crucial for
assays with 1 pM analyte concentration.
2.3.3. Influence of the feature area on the binding kinetics
The density of active capture sites in surface immunoassays usually plays an
important role in defining the maximum number of analyte molecules that can
be captured and therefore the maximum signal surface density that can be
reached. Preventing the denaturation of capture antibodies during and after
their deposition is therefore important, and methods to orient antibodies so
as to have their epitope-binding part exposed at the surface-liquid interface
are sometimes employed. As explained above, we based most of our modeling
on feature areas of 1500 and 150 nm2, but now also investigate the role of
the feature area on the efficiency of the assay for 1 nM and 1 pM analyte
concentration in more detail, Fig. 2.4. We are in particular interested in
learning how the feature area affects assays that have critical requirements
such as utilizing a very small amount of sample or being fast. We therefore
modeled the analyte exploitation for 300 s long assays using the same flow
rates as before. As expected, all graphs in Fig. 2.4 show that the surface-
density of captured analytes increases with the inverse of the feature area so
that the exploitation of analyte is maximal with a feature area of 150 nm2.
The capture and analyte exploitation are particularly sensitive to the feature
area for flow velocities ≤ 0.07 mm s−1. The binding constants kon and koff in
Eqn. 2.5 enforce the same time to equilibrium for different surface densities of
the capture area: the number of capture events per unit of time is larger for
surfaces having a higher density of capture sites but the maximum number of
capture events is also proportionally larger on these surfaces. As an example,
23
2. Modeling and Optimization of Microfluidic-based Immunoassays
0 5000 1000015000
0
50
100
0 5000 1000015000
0
50
100
0 5000 1000015000
0
500
1000
0 5000 1000015000
0.0
0.5
1.0
(a)
 
 
A
na
ly
te
 e
xp
lo
ita
tio
n 
[%
]
 
(c)
 
Feature area [nm2]
 
1 nM
(b)
 
 
C
ap
tu
re
d 
m
ol
ec
ul
es
 [µ
m
-2
]
 0.7 mm s-1
 0.07 mm s-1
 0.007 mm s-1
1 pM
(d)
Feature area [nm2]
Figure 2.4. Efficiency of the capture of analyte molecules flowing at various velocities in a
microchannel as shown in Fig. 2.1 as a function of feature area and analyte concentration
and for the first 300 s of the assay. The ratio between analyte molecules flowing in the
microchannel and analyte molecules captured defines the analyte exploitation (a, c) and
the resulting density of analyte molecules captured on the surface (b, d). The lines are
provided as guides to the eye.
an assay where the feature area is 150 nm2 (first data points) is able to capture
∼ 20 % of the analyte molecules when the analyte solution has a concentration
of 1 nM and a flow velocity of 0.7 mm s−1, Fig. 2.4a. This corresponds to an
analyte exploitation of 20 %. The analyte exploitation falls off dramatically
if the feature area is ≥ 1500 nm2. Reducing the flow velocity will, however,
increase the analyte exploitation significantly. The analyte exploitation is
∼ 86 % when the feature area is 1500 nm2 (second data points) and the flow
velocity 0.007 mm s−1, for example.
The signal in the assay is proportional to the surface density of captured
analytes, and we therefore need to consider what the effect of the feature
area on the number of analytes captured per unit area is, Fig. 2.4b. For
feature areas ≤ 1500 nm2, the density of captured molecules is sensitive to
the flow velocity and maximum for a velocity of 0.7 mm s−1. We learned from
Fig. 2.4b that for these conditions the analyte exploitation is poor, but the
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overall number of analyte captured is the highest. The capture step of the
assay here is clearly transport-limited. For feature areas ≥ 7500 nm2, the
number of captured molecules is small and not sensitive to the flow velocity.
Comparing the signals obtained for different flow velocities in the transport-
limited regime, a slow velocity of 0.007 mm s−1 gives a very small signal
compared with that for a velocity of 0.07 or 0.7 mm s−1. Assays done with an
analyte concentration of 1 pM exhibit a similar behavior as those with 1 nM
analyte concentration, Fig. 2.4c and 2.4d, except that the density of captured
molecules is always ∼ 1000 times smaller.
We have so far analyzed the performance of the assays done in a microchan-
nel for two key analyte concentrations, and will next explore in more detail
how the analyte concentration affects the analyte exploitation, the density of
analytes captured on the surface, and the time needed to reach equilibrium.
We will also evaluate the influence of the binding constant on the assay.
2.3.4. Effect of the analyte concentration on the analyte
exploitation
Both the analyte concentration and the binding constant K determine the
maximum density of analytes captured on the surface at equilibrium. Eqn. 2.6
shows that a maximum of 0.1 % of the capture sites can bind an analyte at
equilibrium when the analyte concentration is 1 pM and the binding constant
109 M−1. This ratio increases to 50 % for an analyte concentration of 1 nM.
We take an arbitrary duration of 300 s for the capture step, flow velocities of
0.7, 0.07 and 0.007 mm s−1, and a 1500 nm2 feature area to investigate how
the analyte exploitation and the density of analytes captured on the surface
vary with the concentration, Fig. 2.5. At analyte concentrations ≤ 1 nM, the
analyte exploitation is nearly invariant with the concentration but is strongly
influenced by the flow velocity, as already discussed in Fig. 2.2. This situation
changes as soon as the analyte concentration becomes larger than K. The an-
alyte exploitation is an important criterion for optimizing the assay when the
total number of analyte molecules in a sample is strongly limited, whereas it
becomes unimportant for high analyte concentration, Fig. 2.5. 300 s suffice to
have nearly all capture sites bound to an analyte when the analyte concentra-
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Figure 2.5. Mean analyte exploitation and surface density of captured analytes resulting
from a 300 s long assay for various flow velocities and analyte concentrations. The binding
constant chosen here was K = 109 M−1. The lines are provided as guides to the eye.
tion is ∼ 10 times larger than the equilibrium constant. Below this concen-
tration value, the surface density of captured molecules diminishes strongly
with the concentration of analyte, as expected from Eqn. 2.5. It becomes
helpful in this case to employ a flow velocity ≥ 0.07 mm s−1 to minimize
transport limitation. Importantly, the model predicts that there will only be
∼ 0.16 captured analyte per µm2 for a 300 s long assay using a flow velocity
of 0.7 mm s−1 and an initial analyte concentration of 1 pM. Assays for such a
low analyte concentration must be longer and if possible should have a smaller
flow velocity. Figure 2.3d showed that a sensitivity of 1 pM can be achieved
using an incubation time of ∼ 2500 s for the capture, which is consistent with
previous experimental work [34].
We now evaluate how strongly high concentrations of analyte affect the time
needed to saturate the capture sites, Fig. 2.6. We know from Fig. 2.5 that sat-
uration of the capture sites can be reached for analyte concentrations≥ 10 nM.
With analyte concentrations ≥ 100 nM, the capture sites are saturated within
a few seconds. An assay to detect an analyte at 100 nM concentration, using
a 1500 nm2 feature area and a flow velocity of 0.7 - 0.07 mm s−1, leads to a
maximum signal after 45 s, according to our model. This illustrates well the
advantage of miniaturizing assays using a microfluidic system. It is preferable
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Figure 2.6. Time to complete saturation of the capture sites as function of analyte concen-
tration. At concentrations ≤ 1 µM, time to equilibrium can be increased by reducing the
flow velocity and the feature area. For analyte concentrations above 10 µM, the capture
sites are saturated in less than 1 s. The lines are provided as guides to the eye.
to reach saturation when the analyte concentration is high, as otherwise varia-
tions in the capture duration render the assay imprecise. Conventional assays
prevent signal saturation and imprecision due to variations of the incubation
time by using a dilution series of the sample. The model shows a relative
insensitivity of the assay to the flow velocity for concentrations ≥ 1 µM. The
assays are in this case clearly reaction-limited.
2.3.5. Influence of the binding constant on the binding
kinetics
The binding constant K between the antigen and the capture antibody plays
an important role on the maximum surface density of analyte molecules that
can be captured at equilibrium. We have seen above that the assay is very
sensitive to the analyte concentration when the concentration falls below K.
As we study the time response of the binding, we need to distinguish the dif-
ferent influences of the association and dissociation constants. The key factors
giving an antibody high or low affinity are the association constant kon and
the dissociation constant koff . The influence of K was therefore investigated
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Figure 2.7. Mean exploitation of analyte volume as function of the binding constant in the
first 300 s of the reaction. An increasing association constant kon (a) results in increased
exploitation of analyte volume, whereas modification of the dissociation rate koff (b) affects
the exploitation of a 1 pM analyte only for K < 109 M−1 using a feature area of 1500 nm2.
for a 300 s long capture step by setting kon from 104 to 108 M−1 s−1 while
keeping koff unchanged and vice versa. Figure 2.7a shows that the analyte
exploitation increases toward 100 % with increasing kon, and the effect of kon
on the analyte exploitation convolves with the flow rate. A significant analyte
exploitation can be observed even for a high flow velocity of 0.7 mm s−1 pro-
vided that kon is very high (108 M−1s−1). Figure 2.7b shows that when koff is
varied and K < 109 M−1, the analyte exploitation is limited because having
koff > 0.001 s−1 results in relatively high dissociation rates. For K ≥ 109 M−1
the association constant dominates the binding reaction, and the analyte ex-
ploitation is only sensitive to the flow velocity.
2.3.6. Comprehensive assay optimizations
The detailed model developed above enables us to propose several strategies
to optimize surface assays in which capture antibodies are present on one
wall of a microchannel and analytes have a concentration of only 1 pM. We
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keep the geometry of the microchannel (30 × 20 µm2 in cross section), the
capture area (500 µm in length), and the binding constant K at 109 M−1
(kon = 106 M−1s−1 and koff = 10−3 s−1) the same as in the previous sections.
In the following discussion we consider that the minimum surface density of
captured molecules that can be detected using a conventional fluorescence
scanner is ∼ 0.5 analyte per µm2 [17]. The remaining parameters influencing
the capture step are the flow velocity (or flow rate), the feature area and the
time for the capture step, all of which are varied in the next simulations. On
a practical level, the flow rate can be changed by varying the evaporation rate
of filled capillary pumps or by changing the depth of the channels.
Optimizing assays for fast measurement
We are interested in exploring how fast a sensitive (analyte concentration
≤ 1 nM) sandwich fluorescence immunoassay can be. The two important
steps in such an assay are the capture of analyte from solution and the bind-
ing of fluorescently-labeled detection antibodies to the captured analyte. The
capture is likely to be the limiting step because detection antibodies are usu-
ally provided at high concentrations (µg mL−1). We therefore focus on the
capture step as it was the case in the sections above. First, we assume that the
available volume of sample does not limit the assay (e.g. volume > 10 µL),
and second, we arbitrarily set the duration of the capture step to 120 s for an
analyte concentration of either 1 nM or 1 pM. This duration is ∼ 12 times
shorter than the capture time used for experiments in which TNF-α was de-
tected with a 1 pM sensitivity [34]. To obtain a sufficient signal in such a short
time, the binding reaction must be very efficient and fast, especially for low
analyte concentration where only a small fraction of the capture sites can be
bound with analytes at equilibrium. A crucial strategy for fast assays is then
to have a high flow velocity to prevent mass transport limitations and a small
feature area to increase the analyte exploitation. Small feature areas might be
achieved by orienting the capture antibody on the surface and/or roughening
the surface used for capture. Figure 2.8 predicts the surface density of ana-
lytes captured on the surface for 150 and 1500 nm2 feature areas. The model
suggests that generating a strong enough signal in only 120 s is not challeng-
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Figure 2.8. Number of captured molecules per µm2 as a function of time for an analyte
concentration in (a), (b) [(c), (d)] of 1 nM [1 pM] and a feature area in (a), (c) [(b), (d)] of
1500 nm2 [150 nm2].
ing when the analyte has a concentration of 1 nM, Fig. 2.8a and 2.8b. The
density of surface-bound analytes should in this case amount to 422 µm−2. A
high flow velocity of 0.7 mm s−1 is beneficial in the case of small feature areas.
At 1 pM analyte concentration, the limit of detection cannot be reached in
120 s if the feature area is 1500 nm2, Fig. 2.8c. A smaller feature area is help-
ful to increase the surface density of captured analytes close to the detection
threshold if the flow velocity is 0.7 mm s−1, Fig. 2.8d. If the flow velocity is
further increased to 2.8 mm s−1 (data not shown), the model predicts that
an analyte concentration down to 1 pM can be measured in 120 s, yielding a
surface density of captured analytes of 0.68 µm−2.
Optimizing assays using minimal volumes of analyte
For some applications, only very limited amounts of sample analyte might
be available and having a fast assay is less important. We now investigate
what the smallest volume of analyte solution needed to detect an analyte at
a concentration of 1 pM is. In this case, the analyte has to be exploited as
much as possible.
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We learned from Fig. 2.4c that an exploitation of the analyte of > 95%
can be achieved by using a feature area of 150 nm2 and a flow velocity of
0.007 mm s−1 (flow rate of 0.25 nL min−1). With this feature area and flow
velocity, the surface density of captured analytes becomes sufficient for detec-
tion after an incubation time of 55 min. This translates into a consumption of
only ∼ 13.8 nL of sample. If the feature area is 1500 nm2 and the flow velocity
is 0.007 mm s−1, the analyte exploitation is ∼ 86 % and the incubation to
achieve sufficient signal increases to ∼ 85 min. In this case, ∼ 21.3 nL of sam-
ple is necessary. A higher signal might be desirable and we therefore consider
the case where the surface density of captured analytes is 2 µm−2, and the
feature area is 150 nm2: The volume of analyte needed with a 1 pM analyte
concentration and a flow velocity of 0.7 mm s−1 becomes ∼ 263 nL and the
assay will take 10.5 min. A slower flow of 0.07 mm s−1 would increase the
analyte exploitation and require a slightly longer assay and much less sample:
25.5 min and ∼ 63.8 nL, respectively.
Increasing the dynamic range of the assay
Many biological assays have a limited dynamic range due to the equilibrium
behavior dictated by Eqn. 2.5. Saturation of the capture sites is easily reached
for concentrations of analyte (e.g. 100 nM) that are higher than 1
K
, and the
surface density of captured analytes diminishes dramatically as soon as the an-
alyte concentration becomes smaller than 1
K
. Sensitive assays will be limited
in dynamic range mostly by saturation at which high analyte concentrations
lead to a fast and complete coverage of all binding sites, which makes it impos-
sible to distinguish between different elevated concentrations of analyte. The
dilution of the analyte sample that solves this problem with assays done using
microtiter plates is not an ideal solution for a microfluidic-based immunoas-
say. We suggest that flushing a solution of analyte through an array of parallel
microchannels at different flow rates can expand the dynamic range of the as-
say. Figure 2.6 suggested that decreasing the flow velocity from 0.7 mm s−1 to
0.007 mm s−1 will increase the time needed to saturate the capture sites with
a 100 nM analyte concentration from 45 to 70 s. The freedom in designing
microchannels of various widths and depths in Si could be used to implement
this strategy. In our previous work, the dynamic range for a sandwich
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fluorescence immunoassay for TNF-α was from 20 pg mL−1 to ∼ 50 ng mL−1,
and we suggest that the upper limit of the dynamic range could be increased
to 1 µM using the method described here.
2.4. Conclusions
Microfluidic networks offer several advantages over conventional microtiter
plates where the assays are done using much larger volumes. However, to
take full advantage of microfluidic networks, it is important to identify the
major parameters of assays in microfluidics as well as their interplay. The the-
oretical model developed here aims at understanding the relative importance
of the transport of analyte in a microchannel by diffusion and convection, the
binding kinetics between an analyte in solution and a surface-immobilized an-
tibody, and the footprint of a capture antibody on the substrate for the assay.
The flow velocity of the analyte solution in the microchannel is probably the
parameter that is the most practical to vary using microfluidics with capillary
pumps or using forced evaporation. Strategies to increase the surface density
and orientation of the capture antibodies can also be applied to enhance the
performances of the assays greatly. The substrate for the assay surface could
be roughened, for example, or capture antibodies could be immobilized via
their Fc part with cross-linkers or protein A or G, or using affinity-contact
printing [48]. Many assays would benefit from using very small amounts of
sample or from being very fast. As the overall number of analyte molecules
in miniaturized assays is typically small (≤ 1 femtomol), it is important to
exploit analytes as much as possible. An exciting outcome of this model is
the indication that an analyte could be detected with picomolar sensitivity
with a capture step of only 2 min duration using appropriately engineered
capture sites. Conversely, longer assays and low flow rates might be used
to perform 1 pM sensitivity assays using a few tens of nanoliters only. The
model presented here and the experimental results obtained previously co-
incide in showing that microfluidic networks have an excellent potential to
miniaturize surface immunoassays that have demanding performances, such
as in point-of-care testing where multiple disease markers could be detected
at low concentrations in a single drop of sample and within minutes.
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3. Continuous Flow in Open
Microfluidics using Controlled
Evaporation
This chapter1 presents a method for programming the flow rate of liquid
aliquots inside open microfluidic network (MFN)s using evaporation while
preventing the undesired evaporation of the aliquots from the MFNs. The
MFNs comprise a number of independent capillary systems, each of which
has a filling port, a microchannel in which assays can be performed, and a
capillary pump (CP) . The capillary systems initially fill owing to capillary
forces. Peltier elements placed underneath the functional zones of the MFNs
dynamically prevent evaporation in all filling ports using the ambient temper-
ature and relative humidity as inputs, and define the flow rate of the liquid
in all microchannels by controlling the evaporation of the liquids from the
CPs. This method achieves flow rates in the microchannels ranging from
∼30 pL s−1 to ∼1.2 nL s−1, and is able to keep 90% of a 0.6 µL solution
placed in an open filling port for 60 min. It is applicable to numerous as-
says or chemical reactions that require appropriate flow control of liquids and
reagents.
3.1. Introduction
Miniaturized platforms such as microfluidics [49] have recently emerged as
powerful (bio)analytical platforms. In particular, the transport of minute
1M. Zimmermann, S. Bentley, H. Schmid, P. Hunziker and E. Delamarche, Continuous
Flow in Open Microfluidics using Controlled Evaporation, first published in Lab Chip,
5, 1355–1359, 2005.
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amounts of liquids in microchannels has opened new possibilities of integra-
tion and parallelization. Microfluidics are used, for example, for cell-sorting
and cellular assays, protein crystallization, immunoassays, DNA analysis, and
medical applications [31, 50]. Each of these applications requires some sort of
pumping mechanism to draw liquids through various functional microfluidic
elements. Several pumping methods based on pneumatic pressure, electro-
osmosis, capillary pressure, coriolis force and electrostatic or piezoelectric
pumps are commonly used for microfluidic applications [51].
A trend in miniaturization is also observed with microtiter plates, which
are typically used for pharmaceutical research (e.g. drug screening), research
in life sciences, and in vitro diagnostics. This trend led to an increase in the
number of test sites per plate and to a reduction of the total sample volume
per test to ∼2 µL for a 1536-well plate.
For both microfluidics and microtiter plates, long times often are needed
to complete assays with low concentration of analytes: assays in microtiter
plates are typically diffusion-limited and necessitate long incubation times,
whereas assays in microfluidics can be reaction-rate-limited. The latter case
is particularly challenging as it requires (i) displacing a small volume of
analyte solution slowly in a microstructure and (ii) preventing undesired
evaporation of sample volume from the microfluidics. Therefore means for
pumping small absolute volumes of liquids accurately and with ultra-low
flow rates are critically required for microfluidics applied to high-sensitivity
assays, Chapter 2. Table 3.1 gives the minimal flow rates for a selected
number of pumping systems.
A simple and yet efficient approach to program ultra-low flow rates in mi-
crochannels is to use controlled evaporation. Examples are the evaporation-
driven pumping for chromatography applications [58, 59] and the valveless
pump for nonpulsatile flow, [60] where the combination of evaporation with
capillary forces generates a continuous ultra-low flow in microchannels.
Continuous low flow rates of ∼5 nL min−1 were achieved in microfluidic
channels, which had integrated heaters and temperature sensors [21]. In that
application, a hydrophobic valve [61] was used to align the liquid-air interface
of a sample with a heating element, and the evaporation rate was defined
by the length of the diffusion path for evaporation. An additional airflow
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Figure 3.1. Method for controlling the flow of liquids in a MFN. The microfabricated MFN
chip comprises independent capillary systems, having as main functional elements a filling
zone, a microchannel providing a reaction zone wherein an immunoassay is performed,
and a pumping zone. Peltier elements placed underneath these zones prevent undesired
evaporation of solution from the filling zone and relay CPs when they are filled with solution.
The Peltier elements are connected to a microcontroller, which continuously tracks the
ambient conditions, calculates the dew point and provides a user interface. Each Peltier
element can be programmed to a certain temperature. The inset shows a picture of the
three Peltier elements that can slide sideway to receive chips of various lengths.
maintained a constant relative humidity at the other end of the diffusion path.
In another work, a sorption agent was employed as a sink for evaporated liquid
to achieve continuous flow rates in microchannels over several hours [62]. This
approach required a closed evaporation chamber.
Here, we present a simplified method to produce a continuous ultra-low
flow rate in a MFN that we want to use for miniatuized surface immunoas-
says. This method is based on (i) controlling the evaporation of liquid from
an evaporation zone by local control of the temperature and (ii) simultane-
ously preventing undesired evaporation of solution elsewhere by cooling. This
method works with open MFNs, i.e. the macroscopic user-interfaces need not
be sealed, but are left open and thus accessible for pipetting.
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The MFNs used here are ∼2 cm2 microfabricated Si chips, similar to those
previously used for combinatorial surface immunoassays having a sensitiv-
ity of ∼1.2 pM and a sample consumption <1 µL per test site [34]. These
MFNs were also used to detect cardiac markers from ∼1 µL samples within
10 min [35]. Independent capillary systems in these chips fill owing to capillary
forces, which makes the chips simple to fabricate and use. The capillary forces
are defined by the geometry and the surface characteristics of the microchan-
nels. A liquid added to a filling port sequentially moves through an appended
microchannel and starts filling a CP. A slab of poly(dimethylsiloxane) (PDMS)
elastomer placed over the microchannels can optionally serve as the substrate
for the assays. Accurately controlling flow rates in filled capillary systems ne-
cessitates both the control, or preferably the prevention, of evaporation in the
filling ports and the control of evaporation in the CPs. This dual requirement
is achieved using Peltier elements onto which the chip is placed, as shown in
Fig. 3.1. A first Peltier is used to cool the zone of the chip in which the filling
ports are located. A second one allows variation of the temperature in the
reaction zone (not used here). Finally, a third Peltier sets the temperature of
the CPs to modulate evaporation and thereby to control the flow of solution
in the microchannels.
The Peltier elements are driven by individual slave modules, which are
programmed by a master module. The electrical part of the system is com-
pletely separated from the microfluidic chip, which is just mounted on the
temperature-controlling unit. Thus, the microfluidic chip does not require
any integrated electrical components for flow control, so that such chips re-
main simple and easy to fabricate.
3.2. Modeling and Experimental Methods
The master module controlling the slave modules measures the ambient tem-
perature and the relative humidity (RH), and provides a user interface. It
calculates the dew point in real time and can command each slave to dynam-
ically track the dew point by a given offset, allowing flexible evaporation and
condensation control. In the slave module, shown in Fig. 3.2, a microcontroller
controls a Peltier driver unit and receives feedback from a thermocouple. The
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Figure 3.2. Functional structure of the temperature-tracking process in the slave modules.
Each slave module receives an individual target temperature value from the master and
measures the temperature of its Peltier element. The accuracy of this algorithm was found
to be ±0.1◦ of an integer target temperature value.
PID routine in the microcontroller of the slave module accurately keeps the
temperature at the programmed offset from the dew point.
If the MFN is completely filled, the evaporation flux je = MD ∂C∂x of liquid
from the liquid-air interface in an open CP determines the flow rate if in the
connected capillary system:
if = ie = MAeD
∂C
∂x
= MAe
D
RT
∂p
∂x
(3.1)
where Ae is the evaporation area, M and D are the molecular weight and
the diffusivity of the evaporating molecules respectively, x is the distance to
the liquid-air interface, and p is the partial vapor pressure of the evaporating
liquid [21].
As we do not employ a convective air flow over the evaporation zone to vary
the flow rate, the transport of the evaporated liquid is dominated by diffusion
and can be calculated using
D∇2p = ∂p
∂t
(3.2)
Eqn. 3.1 and 3.2 cover the most important parameters for evaporating a
liquid: we modify Ae by varying the coverage of the CP and p by varying the
local temperature to regulate the flow. A larger value of p also speeds up the
diffusion of vapor. Our boundary conditions are 100% relative humidity at
the liquid-air interface and ambient conditions far away from the interface.
More detailed models for evaporation from a liquid meniscus or thin films can
be found in literature [63, 64].
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3.2.1. Experimental
The MFNs used here comprise 11 independent capillary systems and sev-
eral monitoring ports (i.e. filling ports, which are not connected to a flow
path) [33, 34]. The structures forming the MFN are produced by vertically
etching Si to a depth of 30 µm. Next, the chip is coated with a thin layer
of sputtered Au, which is then derivatized with a hydrophilic monolayer of
poly(ethyleneglycol) (PEG) (inside the filling structures) and a hydrophobic
monolayer (non-filling areas). First, the stability against evaporation of liq-
uids pipetted into monitoring ports is assessed using an optical microscope. In
a next step, liquids containing fluorescent beads are added to the filling ports
and their velocity is tracked in the microchannels using a fluorescence micro-
scope and the particle-tracking algorithm of a commercial software package
(Image Pro Plus).
3.3. Results
3.3.1. Controlling/preventing evaporation in the filling
ports
Ideally, evaporation is limited to the evaporation zone: If evaporation of liq-
uid occurs elsewhere (e.g. in the filling ports), the concentration of analytes
and reagents will increase and variable flow rates will occur in the capillary
systems.
The evaporation of a 0.6 µL droplet of deionized water placed in a monitor-
ing port is shown in Fig. 3.3. The diameter and the height of the droplet were
measured by viewing it from the side and its volume was calculated. A droplet
that is dispensed in a monitoring port evaporates within 10 min if there is no
temperature tracking of the dew point. Evaporation is significantly reduced
if the dew point is tracked at ∆T = 2 K. In this case, 75% of the droplet still
remains in the port after 15 min. If the offset from the dew point is further
reduced (∆T = 0 K) 75% of the volume remains in the port after 30 minutes.
At temperatures below the dew point, small droplets start to condense around
the ports. We observed that for ∆T = –2 K these droplets typically do not
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Figure 3.3. Evaporation of a 0.6 µL droplet dispensed in a monitoring port, which is main-
tained at a temperature ∆T from the dew point. The lines are provided as guides to the
eye.
coalesce, and the droplet placed in the monitoring port does not grow for
tracking periods of up to an hour. A temperature gradient probably increases
the effective temperature at the surface of these “large” (2-mm-high) droplets
and accounts for these observations. With ∆T = –2 K, 90% of the dispensed
sample volume remains in the filling port after 60 minutes. Such a duration
should be sufficient for assays requiring long incubation times without leading
to detrimental changes in analyte concentration. Longer durations sometimes
resulted in the coalescence of droplets, which occasionally made contact with
the liquid in the filling port, thereby providing a pathway for sample loss from
the filling port or for dilution.
3.3.2. Programming the flow rate
Dispensing a sample of liquid into the filling port of a capillary system results
in the filling of the microchannel and CP connected to the filling port. The
flow rate of the solution in the microchannel is defined by the capillary pressure
exerted by the CP and the flow resistance of all filled parts. Evaporating liquid
from the CP by raising the temperature in the pumping zone to a value above
the dew point introduces a small flow in the connected microchannel, which
was monitored by tracking the 2.5 µm large fluorescent beads flowing in the
microchannels, Fig. 3.4. The beads were moving at constant velocity and in
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Figure 3.4. Tracking the flow of liquid in microchannels using fluorescent beads. The
2.5 µm large latex beads are tracked over time, and the velocity is measured. The mean
flow velocity was estimated using the fitted peak velocity of the beads.
stable position within the channel. A video camera recorded the movement of
these beads while the temperature in the evaporation zone was being modified
to vary the flow rate in the microchannels.
The flow in the microchannels is laminar and has a parabolic flow profile,
which was used to estimate the peak flow velocity, Fig. 3.5. A flow rate of
∼10 pL s−1 can be achieved in the 30 × 30 µm2 wide microchannel while keep-
ing the pumping zone at a temperature equal to the dew point (∆T = 0 K).
Here, the CPs are not covered and the air-liquid interface is∼1 mm2. Tracking
the dew point using ∆T = 30 K increases the flow rate to 1.2 nL s−1. Larger
flow rates can of course be obtained by increasing the liquid-air interface of
the CPs. If we use the modeled assumptions and combine Eqn. 3.1 and 3.2, we
obtain flow rates that compare well with those achieved in the experimental
part (calculations not shown), even hough the model does not consider three-
dimensional diffusion and thermal flow at the interface. The slightly parabolic
relationship between ∆T and the flow rate if provides convenient control of
the flow rate in the microchannels.
A further adjustment of the flow rate can be achieved by partially covering
the CPs using a PDMS layer. In Fig. 3.6, for example, the 11 CPs of a
MFN were covered from 0 to 90% of their surface area. This resulted in a
sixfold difference in speed between the microchannels with the most and the
least covered CPs when the tracking temperature was between 2 and 30 K
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Figure 3.5. Mean flow velocity and flow rate of a solution moving in a microchannel and
filling the CP wherein liquid is evaporated by changing ∆T.
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crochannels of a MFN chip is achieved by covering the CPs with a layer of PDMS. The
lines are provided as guides to the eye.
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above the dew point. Taking an evaporation area of ∼0.4 mm2 and setting
the temperature at ∆T = 7 K from the dew point results in a flow rate of
∼30 pL s−1. We observed that 90 s only were needed to reduce or increase
the flow rate by a factor 10 by varying the tracking temperature. This time
was sufficient to maintain the temperature of the Si chip and a 5 mm thick
aluminum block between the chip and the Peltier element.
3.4. Conclusions
Temperature-controlled evaporation is well suited to control flow even at very
low flow rates in open MFNs provided that evaporation is prevented in those
areas of the MFNs where liquids are initially loaded. The design of CPs
and their sealing can be combined to define the upper and lower ranges of
the flow rates. Ultra-small flow rates (i.e. < 100 pL s−1) provide a unique
opportunity to perform high-sensitivity assays using microliter volumes of
sample. A sample with a volume of 2 µL, which can be used with 1536-well
microtiter plates, could flow in a MFN for more than 9 h at a flow rate of
60 pL s−1. With the same flow rate and using a sample of 50 nL, an assay
could still last for ∼14 min and simultaneously provide sufficient time for
performing immunoassays having sub-nanomolar sensitivity.
It is also possible to modulate the flow rates in the microchannels by adjust-
ing the evaporation in the CP to optimize the time needed for reaction with
each successive reagent. To set the flow rates of liquids in the microstructures,
MFN chips require neither integrated components nor expensive peripherals.
This method therefore expands the versatility and hydrodynamic performance
of MFNs without departing from the original goal of developing a flexible tech-
nology for ultraminiaturized biological assays. This method could also be used
to study how cells immobilized in microchannels respond to slowly delivered
substrates.
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4. Screening Cell Surface
Receptors using Micromosaic
Immunoassays
This chapter1 presents a general method for screening cell surface receptors
using so-called micromosaic immunoassays. This method employs a microflu-
idic chip having n (n = 11) independent flow paths to move cells over m
(m = 11) lines of surface-patterned antibodies for screening individual cells
in a parallel, combinatorial, fast and flexible manner. The antibodies are pat-
terned as 30 µm wide lines on a poly(dimethylsiloxane) layer used to seal the
area of the chip in which screening is being monitored. Mouse hybridoma
cells having CD44 cell surface receptors and anti-CD44 antibodies were used
to establish a proof-of-concept for this method. Both the capture antibodies
and the cells were fluorescently labelled to allow the position of the cells to
be accurately tracked over the binding sites using an inverted fluorescence
microscope. The chips and cells were maintained at a constant temperature
between 20 to 37 ◦C, and flow velocities of the cells over the capture areas
were 100–280 µm s−1, resulting in a ∼0.1–0.3 s residency time of the cells on
each of the eleven 30 × 30 µm2 capture areas. Binding of the cells appeared
to be specific to the capture areas, with a yield of ∼30 % when the assay was
performed at a temperature of 37 ◦C and with a slow flow velocity. We suggest
that this proof-of-concept is broadly applicable to the screening of cells for
medical/diagnostic purposes as well as for basic research on the interaction of
cells with surfaces.
1M. Wolf, M. Zimmermann, E. Delamarche and P. Hunziker, Screening Cell Surface Re-
ceptors using Micromosaic Immunoassays, first published in Biomedical Microdevices 9,
135–141, 2007.
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4.1. Introduction
Cellular assays are used to study how chemicals, biomolecules and factors
such as electrical and mechanical stimuli, radiation, and heat affect the via-
bility, metabolism, differentiation, cytoskeleton, motility, adhesion, receptor
trafficking, and apoptosis processes of cells [65]. Cellular assays therefore are
of fundamental importance in biology, medicine, pharmacology, and biotech-
nology. They are used both at a fundamental research level as well as for
diagnostics. Whereas many assays focus on changes in the morphology, activ-
ity, or colour (due to staining) of cells, several assays aim at identifying cell
membrane receptors to classify cells, detect diseases, or elucidate biological
pathways [66].
Cellular assays are also increasingly being used to test the safety of drugs
and to identify potential drugs for cellular receptors. Cellular assays can
require testing thousands of compounds at various concentrations, using indi-
vidual compounds or a combination of compounds [67]. Clearly, these assays
can benefit from miniaturization by decreasing the size and cost of the in-
frastructure and equipment needed [68, 69]. In addition, cells such as stem
cells and cells from some mammalian cell lines are available in very limited
quantities only.
Microfluidics are emerging as a powerful class of devices for performing
miniaturized cellular assays [70, 71, 72], patterning cells, [73, 74] and control-
ling cellular environments [75, 76, 77]. These devices can accommodate micro-
liter and sub-microliter volumes of samples and reagents, can provide faster
time to results than conventional technologies, can effect multiple assays in
parallel or serial assays with high throughput, and sometimes are portable.
We have developed a class of microfluidics in which liquids move under the
action of capillary forces [78, 79]. These microfluidic chips are autonomous
and do not need pumping elements. They can be used without peripherals
for actuation. We call one independent flow path on such a microfluidic chip
a capillary system (CS) [33]. CSs can be cloned and arrayed so as to move a
number of solutions independently and run assays in parallel. Key to using
these chips is the accurate patterning of receptors for analytes on the surface
of a PDMS elastomer, which reversibly seals sections of the CSs.
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Assays based on this approach can be two-dimensional and combinatorial.
A first microfluidic chip with n CSs can be used to pattern n types of capture
antibodies (Abs) on PDMS as parallel lines. A second chip having m CSs can
be used to bringm samples over the surface-immobilized capture Abs. Ligand-
receptor interactions between the capture Abs and their antigens from solution
result in a maximum of n × m binding interactions, which can be displayed
as a “micromosaic” of fluorescence signals if fluorescently-tagged detection
Abs are used to reveal where antigens are captured on PDMS [14]. Similar
approaches for the combinatorial screening of clinical analytes [80, 81, 82] and
single-stranded DNA analytes have been developed [83]. A matrix of surface
binding interactions can also be used to detect flowing antigens with a serial
dilution strategy [84].
In this chapter, we explore how the concept of micromosaic immunoassays
[14] can be applied to the screening of cells. Several reasons motivate this
work. First, micromosaic immunoassays are efficient. One microliter of sample
or less is sufficient to screen eight or more types of analyte. The short paths
for diffusion of analytes in microchannels can greatly accelerate diffusion-
limited steps. The flow of solutions in microfluidics is typically laminar and
makes rinsing steps short and effective. A fluorescent sandwich immunoassay
having ∼10 steps can be done in less than 10 min for detecting analytes at a
concentration level of ∼10 nM or in ∼45 min for analytes at concentrations
down to 1 pM [34, 35]. This method suggests that cells can be screened
rapidly and using small volumes of sample. Second, using microfluidic chips
the PDMS substrate for the assay can be patterned in a flexible manner prior
to analyzing samples [49]. The accurate patterning of capture Abs on a PDMS
surface limits the depletion of analytes from a small volume of sample and
facilitates the reading of a large number (up to several hundreds) of fluorescent
signals. The PDMS layer can be readily removed from the microfluidic chip
at the end of the assay and the signals analyzed using a fluorescence scanner
or microscope. With respect to cellular assays, it should then be possible
to localize the interaction of cells with surface-bound receptors accurately.
Third, the possibility to conduct assays and calibrate them simultaneously
using reference samples may yield a better consistency and smaller intra-
assay variation than assays do that are done as independent experiments.
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Similarly, it should be possible to screen different types of cells in parallel
using a micromosaic format. In the remainder of this chapter, we first review
how a micromosaic immunoassay for screening cells can be set up and then
provide a proof-of-concept by analyzing the trajectories of individual cells
passing in microchannels over surface-immobilized antibodies.
4.2. Experimental
4.2.1. Chemicals and cells
Chemicals were purchased from Sigma-Aldrich or Fluka (Buchs, Switzerland)
unless otherwise stated. Cells from the mouse hybridoma cell line PK136 were
used for this work. Briefly, these cells secrete mouse IgG2a monoclonal anti-
body, which reacts with mouse natural killer cells. These hybridomas were ob-
tained by fusion between SP2 myeloma cells and spleen cells (C3H × BALB/c)
immunized with mouse spleen cells [85, 86]. The cells were cultured and pre-
pared using phosphate-buffered saline (PBS) with pH 7.4, bovine serum al-
bumin (BSA), Tween 20, fluorescein diacetate, dimethylsulfoxide (DMSO),
Iscove’s Modified Dulbecco’s Medium (Gibco, Invitrogen, Switzerland), foetal
calf serum, normal mouse serum, hyaluronidase, and propidium iodine. The
cells were cultured with 5 % atmospheric CO2 at 37 ◦C in Iscove’s Modified
Dulbecco’s Medium, which was supplemented with 10 % foetal calf serum, in
a cell incubator.
Anti-CD44 monoclonal antibodies (BD Biosciences, San Jose, CA), either
conjugated with fluorescein isothiocyanate (FITC) or Phycoerythrin, were
used as capture antibodies for the microfluidic-based assays (see below) as
well as for fluorescence activated cell sorting (FACS). FACS (FACScan, BD
Biosciences, San Jose, CA) was used to verify the presence of CD44 on the
PK136 cells before performing microfluidic-based assays as follows. First, cells
were taken from the cell culture and washed, resuspended in PBS at a concen-
tration of 2.5 × 106 cells mL−1, and 200 µL of the suspension was loaded into
the wells of a 96 microtiter plate (Falcon), which corresponds to ∼500,000 cells
per well. The cell aliquots were centrifuged, and their Fc receptors (a poten-
tial nonspecific cellular receptor for antibodies) blocked using 100 µL solution
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of mouse serum in PBS (1:50) for 15 min at room temperature. To label the
CD44 cellular receptors fluorescently, the cells were centrifuged again and in-
cubated in a 1:200 solution of antibody (anti-CD44-Phycoerythrin conjugate)
in 0.1 % normal mouse serum in PBS for 15 min at room temperature. The
cells were centrifuged and resuspended in 200 µL of PBS twice. Immediately
prior to FACS, propidium iodine was added to sort out nonviable (necrotic)
cells. Viable cells were assessed using FACS scatter plots by gating on pro-
pidium iodine-negative populations.
Cells for the microfluidic-based assays were handled and stained as follows.
A suspension of PK136 mouse hybridoma cells was taken from the cell culture
and incubated for 1 h at 37◦C with hyaluronidase (5000 IU per ∼5 × 106 cells
mL−1) to prevent hyaluronic acid-mediated cell aggregation [87]. To visualize
the cells during the assays, 0.1 µL of a 5 mg mL−1 solution of fluorescein
diacetate in DMSO was added to 1 mL of cell suspension. After 30 min of
incubation at room temperature, the cells were washed three times with PBS,
resuspended in a 2 % solution of normal mouse serum in PBS, and used after
a minimum resting time of 15 min.
4.2.2. PDMS and microfluidic chips
The prepolymers of PDMS (Sylgard-184, Dow Corning, Midland, MI) were
mixed at a 10:1 ratio using a Dopag Mixer (Cham, Switzerland), dispensed
on the bottom of a Falcon Petri dish, and cured for at least 24 h at 60◦C.
PDMS slabs of desired dimensions were then cut and used to prepare lines of
capture Abs or simply to seal some areas of the chips during the assays.
The microfluidic chips were microfabricated using photolithography. A
chrome mask was used to pattern a photoresist on 4” silicon wafers and to
etch selectively 20 µm of silicon using a deep reactive ion etcher (STS ICP,
Surface Technology Systems plc, Newport, U.K.). After removal of the pho-
toresist, the wafers were coated with Ti (10 nm) and Au (150 nm), and then
diced to yield individual chips. Each microfluidic chip had 11 independent
CSs [34]. The top surface of each chip was microcontact-printed with octade-
canethiol to form a hydrophobic coating (advancing contact angle with water
of ∼115◦). The chips were then immersed in a 10 mM ethanolic solution of
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thiolated poly(ethylene glycol) (ABCR, Karlsruhe, Germany) for 30 s to make
the recessed areas of the chips wettable (advancing contact angle with water
of ∼40◦) and protein-repellent. Used chips were cleaned prior to reuse by
immersion in a “Piranha” solution (H2SO4:H2O2, 3:1, CAUTION) [88], after
which the chips were copiously rinsed with deionised water and dried under a
stream of N2. The surface of the chips was freshly prepared before each use.
4.3. Patterning of Capture Antibodies and
Screening Assays
Capture Abs were patterned on PDMS by covering the microchannels of a
chip with a ∼1-mm-thick slab of PDMS and filling the loading pads of the
chip with 0.5 µL of a 0.1 mg mL−1 PBS solution of anti-CD44 Ab conjugated
with FITC . After 2 min, most of the Ab aliquots had passed through the
microchannels, which were flushed by adding (i) 0.5 µL of a 1 % solution of
BSA in PBS and (ii) 0.5 µL of PBS to the loading pads. Finally, the PDMS
layer was removed manually from the chip, rinsed with deionised water and
blown dry under a stream of N2.
Next the PDMS layer was brought into contact with a second microfluidic
chip so as to expose the lines of capture Abs orthogonally to the microchan-
nels of the second chip. A slab of PDMS was used to seal the capillary pumps.
The chip was then placed on a thermally conductive adhesive, which covered
a thermoelectric element. The cellular assays proceeded by filling the loading
pads of the chip with ∼0.5 µL of a 1 % BSA solution in PBS and ∼0.5 µL of a
107 cells mL−1 suspension of PK136 hybridomas. During the filling of the cap-
illary pumps, air trapped in the pumps slowly diffused through PDMS, which
resulted in a slow and homogenous flow rate of solution in all microchannels.
After dispensing the cells, two cover glass slides separated by a 1-mm-thick
PDMS frame were quickly placed over the chip and its thermoelectric element.
The thermoelectric support with the chip and glass slides were turned upside
down and placed on the stage of an inverted fluorescence microscope (Axiovert
100, Zeiss, Switzerland). A thermo-regulator (TC2812, Minco, Niederuzwil,
Switzerland) with pulse-width modulation and thermo sensor was used to
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Figure 4.1. Experimental setup for a micromosaic immunoassay screening of cells.
Aliquots of cell suspensions are placed in the loading pads of independent capillary sys-
tems, from where they fill the microchannels and capillary pumps of the capillary systems.
As the cells cross lines of capture Abs, which are patterned on a sealing PDMS layer, cap-
ture of some cells may occur. A heater, two glass slides, and conductive foil spacers form a
chamber inside which the microfluidic chip and the cells are maintained at a constant tem-
perature; moreover evaporation of water from the loading pads is negligible. The trajectory
of the cells in the region of the capture sites is monitored in the X- and Y -directions using
an inverted fluorescence microscope and recorded as a video for analysis. The fluorescence
microscope images show (left) three lines of capture Abs (orange) and a cell (green) moving
in one microchannel and (right) ∼300 nL of cell suspension in one loading pad.
regulate the temperature of the thermoelectric element and chip from 20 to
37 ◦C. A digital camera (Coolpix E990, Nikon) was used to record the tra-
jectory of cells flowing over the region in which the capture Abs are located.
The focal plane of the microscope was set to the lines of capture Abs. The
videos showing the trajectories of the cells were analyzed after the assay using
the software Image Pro and its object-tracking functions.
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4.4. Results and Discussion
The influence of the environmental parameters (e.g. culture medium, pH,
temperature, shear stress) on the metabolism of living cells and the tendency
of cells to sediment require the adaptation of micromosaic immunoassays to
the particular needs of living cells. The setup used for screening cells using CSs
is displayed in Fig. 4.1. It consists of a microfluidic chip of silicon, covered with
a thin layer of Au and self-assembled monolayers, and has two separate blocks
of PDMS. One block serves as the substrate for the assay: it is patterned with
lines of capture Abs and placed on the region in which the microchannels of the
CSs run parallel. The second PDMS block covers the capillary pumps of the
CSs. It helps to maintain a reproducibly low flow rate in the microchannels
when the solutions added to the loading pads progressively displace air from
the CS and fill the capillary pumps. To prevent cell lyses due to fast cell
flow in the microchannels, a small volume of buffer is added first to each
loading pad so as to fill the microchannels up to approximately the inlet of
the capillary pumps. During the assay, the air compressed by the filling liquid
permeates through the PDMS, resulting in a slow flow of solution inside the
microchannels. The microfluidic chip is placed on a heat-conductive adhesive
and heating device. Once the solutions with cells are loaded on the chip, the
chip and its heating element are placed upside down on the stage of an inverted
fluorescence microscope. Two glass slides separated by ∼1-mm-thick slabs of
PDMS insulate the chip from the microscope stage to prevent condensation of
water in front of the microscope’s optical path. The chip was maintained at
a constant temperature between 20 and 37 ◦C for the assays. Sedimentation
of cells resulted in cells coming into contact with the capture sites. The
fluorescence images in Fig. 4.1 show cells labelled with fluorescein (green)
and capture sites on PDMS having antibodies labelled with R-phycoerythrin
(orange).
For the proof-of-concept shown here, we selected mouse hybridoma cells
having a CD44 cell surface receptor. These cells partly derive from white
blood cells, and CD44 is involved in numerous cell-cell interactions important
for lymphocyte activation, hematopoiesis, and tumour metastasis. In addi-
tion, the transmigration of blood vessel walls by white blood cells is a physi-
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ological process, which is mediated by rolling and tethering through receptor
molecules in the cell membranes [89, 90]. This cell-binding mechanism guides
immunocompetent cells to inflammatory target areas. The receptor profile
expressed and displayed by the endothelial cells provides specificity for sub-
populations of white blood cells that can be differentiated by their membrane
protein expression, that is their cluster of differentiation (CD) [89]. Using
a micromosaic immunoassay and specific antibodies, it should be possible to
imitate the capture of a subpopulation of white blood cells on the surface
of blood vessels to a certain extent: depending on the combination of anti-
body and receptor, rolling, tethering or firm binding of leukocytes to a surface
may occur under a certain shear rate. In clinical medicine, the examination
of white blood cell subpopulations is crucial for diagnosis and treatment of
diseases, e.g. AIDS. A device capable of separating subpopulations would
allow further examination of these cells or an isolated ex vivo treatment of
these cells and their reinsertion into the blood stream. In current clinical
practice, conventional FACS machines require incubating the cell sample to
be examined with fluorescently labelled antibodies for at least half an hour.
The cellular assays consist in following the real-time trajectories of the cells
in each microchannel along the main axis of the microchannel (X-coordinate)
and orthogonal to the microchannel (Y -coordinate). Fig. 4.2 shows the tra-
jectory of cells in 11 independent microchannels with the microfluidic chip
maintained at 20 ◦C. First, ∼140 cells are tracked during 42 s and their Y -
positions are analyzed, Fig. 4.2a. Short segments in this graph correspond
to cells entering and leaving the channels without noticeable interaction with
the capture Abs. On average, the cells remain ∼2.5 s in the length of the
microchannels that is visible in the field of view and their mean velocity in
the microchannel is ∼280 µm s−1. Note that the curvature of the segments
reflects an optical artifact and not a curved trajectory of the cells in the mi-
crochannels. In addition, several cells bind to the capture areas and become
immobile during this experiment. The graph in Fig. 4.2b shows the trajectory
of selected cells along the main axis of the microchannels as a function of time.
Cells flow along the microchannels at a steady speed until they become bound
to one of the 11 capture zones they cross.
Figure 4.3 shows selected frames of a video in which the trajectory of cells
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Figure 4.2. Trajectories of PK136 hybridoma cells having CD44 surface receptors and
flowing inside microchannels across patterned lines of anti-CD44 Abs. (a) Graph showing
the lateral positions of the cells inside the microchannels as a function of time. The entrance
and exit coordinates of one cell flowing through a microchannel without binding are marked.
Following a binding event, cells acquire an invariant Y -coordinate. (b) Graph showing the
longitudinal position of cells along the microchannels as a function of time. Cells flow over
11 areas having capture Abs. The trajectories of only a few binding cells are depicted for
better clarity.
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Figure 4.3. Outline (a) and movie frames (b - h) illustrating a micromosaic immunoassay
with cells as recorded using a fluorescence microscope and video camera. The cells are
PK136 hybridomas, have CD44 surface receptors, and are labelled with a fluorescein dye
(green). Anti-CD44 Abs labelled with fluorescein, which are patterned as lines on a PDMS
layer used to seal the microchannels, form the capture areas. The cells flow from left to
right inside 30 µm wide microchannels. The cells binding to anti-CD44 Abs are circled.
The video corresponding to this assay is provided as supplementary material [91].
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over the capture areas was followed. This experiment was done at 37 ◦C to
optimize the chances of binding of the cells. The fluorescently-labeled capture
Abs appear faint as a result of photobleaching, whereas cells appear as bright
green ∼10–15 µm wide spheres. The frames cover a timeframe of ∼20 s during
which the cells flowed with an average velocity of 150±45 µm s−1 or equivalent
flow rate of ∼0.15 nL s−1. This range of velocities is mainly due to the laminar
flow profile, which transports cells positioned in the center of the microchannel
faster than those positioned elsewhere. The average residence time of one
cell above one 30 × 30 µm2 capture area is 0.2 s. A basic analysis of the
trajectories and binding of the cells using commercial vision software revealed
that ∼30 % of the cells were captured on one of the 11 capture sites aligned in
each microchannel. A more detailed analysis would require the identification
of the three-dimensional position of the cells in the microchannels and the
calculation of the specific velocity and residence time on the capture areas for
each cell. Such an analysis could for instance use methods known from particle
image velocimetry, which requires a high-speed imaging setup. Interestingly,
the retardation of some cells passing over surface-immobilized receptors can
yield insight into the protein expression of retarded cells [92]. This suggests
that qualitative cellular assays can provide useful information without the
need for full parameterization of the factors governing the interaction between
the cells and the receptors.
The flow rate of the cell suspension may be varied using peripheral equip-
ment having several heating/cooling elements placed in contact with the mi-
crofluidic chip, Chapter 3, to study the effect of hydrodynamic forces on the
behavior of immobilized cells [93]. The direction of flow, for example, can be
changed back and forth to obtain statistical information on the binding of one
cell over one type of capture area. In addition, micromosaic immunoassays
for screening cell surface receptors can be combined with an interrogation of
the mechanical properties of cells (size and elasticity) to identify particular
cells, such as cells that are infected with parasites [94].
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The proof-of-concept shown here can be further refined. First, many types of
capture Abs may be used to screen for various types of cells or receptors simul-
taneously. This may require using cells that are labeled differently in a first
step when developing the assay. Second, the geometries of the microchannels
and capture sites can be varied to capture cells at particular locations. This
could minimize or prevent the risk of collisions and interferences between flow-
ing and surface-immobilized cells. Third, “advanced” capillary pumps can be
designed, see Chapter 5, so as to vary the flow conditions in the microchannels
and to study the influence of the flow rate on the statistics of binding. In this
paper, the emphasis was to miniaturize the assays and screen individual cells
from microliter volumes of samples. Larger volumes of sample can of course
also be used, and capture sites can be made much larger and continuous, for
example. The setup, microscope, camera and chemicals used here are rela-
tively standard and did not require any particular modification for the assays,
except for holding the microfluidic chips on an element having a controlled
temperature.
We believe that the work shown here is broadly applicable and provides a
flexible and efficient method for screening cell surface receptors. This con-
cept may be used for histocompatibility testing to screen human leukocyte
antigens. It can also be used for blood typing and for verifying the pres-
ence of cells in routine applications in which samples are available in limited
volumes. There is a number of diagnostics that require the analysis of the
number and type of white blood cells, and the status of some diseases such
as HIV can be monitored by counting CD4-T-cells, for example. Although
we are mainly interested in developing simple research and diagnostic plat-
forms based on capillary-driven microfluidics, actuation mechanisms may be
added to the microfluidic chips used here for sorting cells [95, 96]. In general,
multidimensional assays are needed when testing large numbers of cells and
compounds to obtain statistically meaningful results. It is therefore desirable
to have cell assays that can screen cell/compound interaction in parallel (i.e.
multiplexed assays), a task at which micromosaic assays excel.
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5. Capillary Pumps for
Autonomous Capillary Systems
Autonomous capillary systems (CSs), where liquids are displaced by means of
capillarity, are efficient, fast and convenient platforms for many bioanalytical
applications. The proper functioning of these microfluidic devices requires
displacing accurate volumes of liquids with precise flow rates. In this chapter,1
we show how to design capillary pumps for controlling the flow properties of
CSs. The capillary pumps comprise microstructures of various shapes with
dimensions from 15–250 µm, which are positioned in the capillary pumps to
encode a desired capillary pressure. The capillary pumps are designed to
have a small flow resistance and are preceded by a constricted microchannel,
which acts as a flow resistance. Therefore, both the capillary pump and the
flow resistance define the flow rate in the capillary system (CS), and flow
rates from 0.2–3.7 nL s−1 were achieved. The placement and the shape of the
microstructures in the capillary pumps are used to tailor the filling front of
liquids in the capillary pumps to obtain a reliable filling behaviour and to
minimize the risk of entrapping air. The filling front can, for example, be
oriented vertically or tilted to the main axis of the capillary pump. We also
show how capillary pumps having different hydrodynamic properties can be
connected to program a sequence of slow and fast flow rates in a CS.
5.1. Introduction
Microfluidic devices are promising for applications that require precise dis-
placement of small amounts of liquids or that can benefit from peculiar be-
1M. Zimmermann, H. Schmid, P. Hunziker and E. Delamarche, Capillary Pumps for Au-
tonomous Capillary Systems, first published in Lab Chip, 7, 119–125, 2007.
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haviours that liquids and chemical reactions exhibit at the micrometer length
scale [97]. At small scale, for example, diffusion times of reactants and ana-
lytes are short, surface-to-volume ratios are large, and surface tension forces
dominate gravitation forces [98, 99]. Accurate control of the flow of liquids
in microfluidics is key to their proper functioning and can be achieved with
either actuated or passive microfluidics. In actuated microfluidics, the flow
is controlled using an external power source or pump and is driven mostly
by displacement, centrifugal, electric-field or magnetic-field pumping mecha-
nisms [51]. Actuated microfluidics are most powerful in pumping on demand
milli- and microliters of liquids for a long time and with a high flow rate. In
passive microfluidics, flow rates are encoded in the design of the microfluidics.
Typical driving forces for propelling liquids in passive microfluidics are, for
example, chemical gradients on surfaces, osmotic pressure, degassed PDMS
[100], permeation in PDMS [101] or capillary forces [102, 103]. Such microflu-
idics fill spontaneously and are appealing owing to their portability, low dead
volume and small power consumption. A combination of actuated and passive
control for moving liquids in microfluidics has also been demonstrated [104].
There, pressurised gas chambers embedded in a plastic chip were separated
from a liquid via thin membranes. Opening these membranes irreversibly
using a thermal actuator caused the liquid to be pushed pushed through hy-
drophobic microfluidic channels at flow rates defined by the geometry of the
channels. We are mainly interested in developing passive microfluidics driven
by capillary forces for use in bioanalytics and for patterning biomolecules on
surfaces [49]. We call such microfluidics capillary systems (CSs) [33]. Passive
microfluidics have also been used for micromoulding in capillaries to study
the dynamics of wetting of liquid prepolymers in rectangular capillaries [105]
or to deposit locally enzymes within capillaries [106]. Passive microfluidics
which require the displacement of large volumes of liquid or very low flow
rates can be enhanced by peripheral equipment, Chapter 3. As the flow rate
of a liquid in passive microfluidics is predefined, minor device variations can
compromise their operation. For this reason, modelling the filling dynamics
[107, 108] of liquids in capillaries is desirable, but for capillary-force-driven mi-
crofluidics the computational fluid dynamic methods require extremely high
grid resolution or adaptive grid refinement algorithms to track the movement
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CRV Reactionchamber Capillarypump
(a) top view
Structures of the
capillary pump
Contact angle of liquid with chip
PDMS sealing cover
Bulk silicon
Loading
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Filling front
Wettable
Flow
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(b) cross view
Figure 5.1. Encoding flow rates of a liquid in a CS using a capillary pump. (a) The
capillary pump is the principal structure determining the flow rate of the liquid in the CS
and can therefore be designed to program this flow rate. A chip having one or several CSs
has a typical area of 1 cm2. The capillary retention valve (CRV) prevents the reaction
chamber from drying out. (b) The pumping power of a capillary pump depends on the
contact angles of the filling liquid with its walls and the characteristic dimensions of its
structures. The various parts in the scheme are not to scale.
of the liquid filling front [109, 110]. Therefore, a high computational effort
is necessary to apply these methods. An alternative method is to use a con-
straint energy minimization approach, but such a method cannot describe the
dynamics of filling [111].
In this chapter we are interested in extending the performance of CSs by
understanding and governing the filling dynamics of liquids in CSs better.
We therefore designed, fabricated and tested a range of CSs, and compared
their experimental filling behaviour with a simple analytical model. We use
CSs that are microfabricated into silicon chips and sealed with PDMS. The
CSs comprise a loading pad, a capillary retention valve (CRV) and a reaction
chamber, in which an immunoassay can be performed, as well as a flow resis-
tance and a capillary pump with a vent, see Fig. 5.1. Surface-immunoassays
can be performed directly on the sealed chip by patterning receptors for ana-
lytes on the PDMS layer [34]. Given the importance of capillary pumps on the
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hydrodynamic performance of CSs, we focus on designing and implementing
new types of capillary pumps in this work. As will be shown below, a flow
resistance in front of the capillary pump can also be used to modulate the
filling behaviour of liquids in capillary pumps. The flow rate Q of a liquid in
a CS is determined by the wettability of the CS, the viscosity of the liquid,
the total flow resistance and the capillary pressure in the capillary pump, and
can be expressed as
Q = 1
η
∆P
RF
(5.1)
where η is the viscosity of the liquid, ∆P the difference in pressure inside
and in front of the liquid, and RF the total resistance to flow of the flow
path. In CSs such as that shown in Fig. 5.1a, a microchannel of variable
length dominates the flow resistance. The resulting capillary pressure Pc of a
liquid-air meniscus in such a rectangular microchannel is
Pc = −γ
(cosαb + cosαt
a
+ cosαl + cosαr
b
)
(5.2)
where γ is the surface tension of the liquid, αb,t,l,r are the contact angles of
the liquid on the bottom, top, left, and right wall, respectively, and a and b
are the depth and width of the microchannel, respectively.
The flow resistance of such microchannels is a geometric term with a Fourier
series and can be approximated by a linear term [25]
RF =
[
1
12
(
1 + 56
a
b
)
abR2H
L
]−1
(5.3)
satisfying the condition a < b. Here L is the length of the microchannel and
RH is the hydraulic radius of the microchannel, RH = 2AP =
ab
a+b , with P being
the perimeter and A the area of the cross section of the microchannel.
The flow in a microchannel can thus be estimated by the capillary pressure
divided by the flow resistance that continually increases as the channel is being
filled. In the case of capillary filling, spontaneous filling of a liquid inside a
microstructure results from the interaction between the surface tension of the
liquid and the chemistry and geometry of the surfaces of the microstructure.
In the following sections, we review how to design capillary pumps for CSs
and show how the capillary pumps enable advanced flow control in CSs.
62
5.2. Experimental
5.2. Experimental
The CSs were fabricated in silicon using photolithography and dry etching.
Briefly, photoplotted polymer masks [112] (Selba S.A., Versoix, Switzerland)
with a resolution of 25400 dpi were used to pattern a photoresist on silicon
wafers. The CSs were etched 30 µm deep into the silicon using a deep reac-
tive ion etcher (STS ICP, Surface Technology Systems plc, Newport, U.K.).
On some CSs the flow resistor was then coated by hand with resist and the
remainder of the CS was etched to a total depth of 60 and 90 µm. Unless
otherwise noted, we will discuss the 30 µm CSs in detail. After removal of the
photoresist, the wafers were coated with Ti (10 nm) and Au (150 nm), and
then diced to produce individual CSs.
The Au surface of the CSs was cleaned in a UV-ozone chamber (UV-Ozone
Photoreactor PR-100, Ultra-Violet Products, Upland, CA) for at least 20 min.
The CSs were then immersed for 30 s in a 2 mM ethanolic solution of thi-
olated poly(ethylene glycol) (HS-PEG 12750-4, Rapp Polymere, Tübingen,
Germany) to make the Au surface hydrophilic. The CSs were rinsed with
ethanol and dried under a stream of N2. The resulting Au surface had an
advancing contact angle of 40◦ with deionised water, to which a food col-
orant was added (Food Colour bordeaux, Werna W. Schweizer AG, Wollerau,
Switzerland). Contact angles were measured using the sessile drop method on
flat surfaces. A few millimetre thick layer of cured PDMS (Sylgard-184, Dow
Corning, Midland, MI) was used to seal the CSs from the capillary retention
valve to the vent. The advancing contact angle of deionised water with PDMS
was 115◦. All surface treatment and sealing steps were executed in a laminar
flow box.
The CSs were used within 5 to 45 min after derivatization of its surface
and sealing. Coloured deionised water was used as a model liquid in the
experiments for this paper. The CSs showed comparable filling characteristics
when other liquids having similar contact angles and viscosities as water were
used (data not shown). To prevent evaporation of liquid from the loading
pads, the sealed CSs were placed on a Peltier stage in a closed chamber and
maintained at a temperature of 1 K above dew point (∼10 ◦C). The chamber
was briefly opened to pipette liquid into the loading pads. The flow rate was
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determined based on the time it required to fill a capillary pump completely.
This time ranged from 45 s to a few minutes. The filling of liquids in the
CSs was observed using a stereomicroscope (Wild Heerbrugg, Switzerland)
equipped with a digital camera (Coolpix E990, Nikon).
5.3. Results and Discussion
5.3.1. Designing advanced capillary pumps
A CS starts filling upon pipetting a liquid into its loading pad. After the
liquid has filled the capillary retention valve, the reaction chamber and the
flow resistor, the liquid front reaches the capillary pump. The total volume
of the elements in a CS located before the capillary pump is generally negli-
gible compared with the volume of the capillary pump. The capillary pump
therefore dictates the flow conditions of the largest volume fraction of liquids
pipetted in the loading pad. Ideally, capillary pumps should be able to gener-
ate a smooth flow of liquid in a CS, to induce flow rates ranging from micro-
to picolitre per second and to fill the CS entirely without entrapping air. In
practice, these requirements can be difficult to meet. This is the case for CSs
that are used to miniaturize surface immunoassays and in which the long (up
to 10 mm) and narrow (cross section ≤ 30 × 30 µm2) reaction chambers pos-
sess a significant flow resistance and thus required capillary pumps having low
flow resistance and high capillary pressure. A large flow resistance can also
build up in a capillary pump that has a large volume capacity. If capillary
pumps having different characteristics are to be connected, it is important to
fill the first capillary pump completely before the liquid proceeds to the next
one. Control over the filling front of a liquid in a capillary pump is therefore
desirable and may also be advantageous if some of the liquid present in the
capillary pump must be retrieved for further analysis or processing.
Figure 5.2 shows different implementations of capillary pumps. The sim-
plest possible capillary pump is a microchannel having a sufficient volume to
accommodate the volume of liquid that needs to be displaced. The next sim-
plest capillary pump is a cavity, which can have supporting posts to prevent
collapse of the soft PDMS sealing cover (“Posts” capillary pump in Fig. 5.2a)
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(b)advanced capillary pumping structures
“Posts” “Tree lines a”
“Symmetric lines”
“Tree lines b”
“Hexagons”
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(a) examples of capillary pumps
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Figure 5.2. Examples of capillary pumps. (a) The characteristic dimensions of the struc-
tures generating capillary pressure in a capillary pump can be varied by changing the density
(“Posts”), shape (“Hexagons”), relative positioning, and continuity (“Tree lines”) of these
structures. (b) Examples of capillary pumps described in depth in this work. All capillary
pumps are shown with a filling direction from left to right.
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[79]. Capillary pressure in the capillary pump can be increased by split-
ting the capillary pump into smaller parallel microchannels (“Tree lines a” in
Fig. 5.2a) [33]. We previously used such capillary pumps to encode a high
capillary pressure in autonomous CSs [33]. The total flow resistance of such
capillary pumps, however, can significantly increase when the microchannels
in the capillary pump are long. An alternative design is to place microstruc-
tures, such as hexagons, at regular intervals inside the capillary pump. These
capillary pumps have a comparatively lower flow resistance because of the
large number of parallel flow paths. They can thus be used when “large”
volumes of liquid must be pumped at constant flow rate [34].
Advanced capillary pumping structures as shown in Fig. 5.2b can further
enhance the pumping capabilities of CSs. Elongated microstructures can be
used to control the filling front of a liquid by imposing various time constants
for the progression of a liquid along different directions of the capillary pump.
A straight filling front can be achieved by using lines, as shown in Fig. 5.2b.
Changing the width (u) of the structures compared with their spacing (v)
affects the progression rates of the liquid in the vertical and horizontal di-
rections: the liquid moves quickly in between two parallel lines, whereas it
spreads more slowly elsewhere. The areas separating microstructures act as
pinning sites, which can delay the progression of the filling front for consider-
able amounts of time. It is preferable to have microstructures with a round
periphery to minimize the occurrence of pinning of the liquid. Reducing the
width of the microstructures in the region where they run parallel (“Balled
lines” in Fig. 5.2b) increases the storage capacity of a capillary pump.
It is important to connect the capillary pump correctly to the remainder of
the CS to ensure that the capillary pressure is sufficiently high everywhere in
the connecting region to draw liquid efficiently from the CS to the capillary
pump. This can be done by gradually expanding the lateral dimension of
the capillary pump and centring one microstructure in the connecting chan-
nel at the entrance of the capillary pump. Interlocked structures, such as
the rounded hexagons in Fig. 5.2b, reduce the time needed for a liquid to
move along the sidewalls of the microstructures and to bridge them. More-
over, the edges of the capillary pump can be made long and similar to the
microstructure lattice to minimize the risk of having the liquid shortcutting
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the capillary pump by rapidly wetting its edges. The last type of capillary
pump shown in Fig. 5.2b (“Tree lines b”) has branched filling regions, which,
once filled, become disconnected from the central flow path. With this type
of geometry, capillary pumps can be programmed to have zones that generate
different capillary pressures and that can be filled one after the other without
continuously adding flow resistance to the CS.
From the set of capillary pumps described in Fig. 5.2, we implemented the
most promising ones into CSs using various characteristic dimensions, mea-
sured their flow rate and characterized their filling behaviour, Table 5.1. We
chose characteristic dimensions to obtain flow rates of a few nanoliters per
second. Such flow rates are typical for high-sensitivity and low-volume assays
[34]. Table 5.1 summarizes the findings for CSs, in which the capillary pumps
have characteristic dimensions of 15–250 µm and which draw liquid with rates
from ∼2 to 4 nL s−1. As expected, the fastest CSs have capillary pumps with
the smallest characteristic dimensions. The “symmetric line”-type capillary
pump with a typical dimension of 15 µm, however, has a smaller flow rate than
expected from the calculations. A reason is probably the high number of sites
in which the meniscus at the liquid front is pinned. A liquid filling this capil-
lary pump exhibits a random filling front – similar to a liquid filling a porous
medium [113] – but this random filling front can be changed to a straight
one by rotating the microstructures in the capillary pump by 90◦. “Symmet-
ric line”-type capillary pumps having larger characteristic dimensions, and
“asymmetric line”-type capillary pumps have a straight filling front, which is
oriented perpendicular to the main axis of the capillary pump. Liquid that
fills “hexagon”-type capillary pumps sometimes runs preferably along the cap-
illary edges, which is typical for most capillaries [114]. Flow rates in “rounded
hexagon”-type capillary pumps are very uniform, because the microstructures
are interlocked so that liquid is less pinned. A reproducible filling front can
be observed in the tree-line capillary pump: Liquid in this capillary pump
fills the individual branches one after the other. All capillary pumps have
an absorption capacity (filling factor) of ∼60 to 75 % of their total volume
and can accommodate ∼0.02 µL mm−2 of liquid for a depth of 30 µm. In our
experiments, the capillary pumps typically had a total volume of 0.3 µL on
an area of 15 mm2. From the analytical model based on Eqn. 5.1–5.3, we
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Figure 5.3. Calculated and experimental flow rates of water in “Symmetric line”-type cap-
illary pumps. For each type of CS, the first number refers to the spacing (in µm) between
the microstructures of the capillary pump and the last number indicates the length (in cm)
of a flow resistor having a cross section of 30 × 30 µm2 and placed before the capillary
pump. The insets are optical micrographs showing the relative size of the microstructures
in the capillary pumps. The scale bars are 50 µm.
estimated a flow rate of 1.7–8.7 nL s−1 for the “symmetric line”-type capillary
pumps. The capillary pumps were modeled as networks of parallel and serial
resistors, each resistor representing a small channel of the capillary pump.
The total resistance was derived using the equivalent network approach and
Ohm’s Law. We assumed a flow resistance of 3.6 × 10−14 m−3, which includes
the exit channel of the loading pad, three parallel, 10 µm wide capillary re-
tention valves, the reaction chamber, and a 30 µm wide and 1 cm long flow
resistor. In Eqn. 5.3 we used a corrected width of b =
√
v2 + 4v2 = v
√
5,
which we observed from the experiments as the typical width of the moving
meniscus in the “symmetric line”-type capillary pumps. We will now discuss
the influence of the flow resistance in front of the capillary pump on the flow
rate and compare the experimental with the estimated flow rates.
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5.3.2. Connecting capillary pumps using microchannels of
different lengths
It is convenient to change the flow rate of a CS without changing the design
of the capillary pump by simply varying the flow resistance in front of the
capillary pump. For example, we varied the flow resistance in CSs using
“symmetric line”-type capillary pumps. The flow rates for these CSs are
displayed in Fig. 5.3 for four different total flow resistances. A capillary pump
has a maximal flow resistance when it is almost fully filled. This resistance can
however be neglected as it is very small and at least 2–3 orders of magnitude
smaller than the total flow resistance of the CS. The predominating flow
resistors used here precede the capillary pump and had a length of 1, 5, 9
and 13 cm and are abbreviated R1, R5, R9 and R13, respectively. For these
CSs, experimental flow rates varied by a factor of ∼18 and ranged from 0.2–
3.7 nL s−1. Flow rates were determined with an accuracy of ±0.1 nL s−1 or
better. In the CSs with the smallest flow resistance (R1), the liquid filled the
capillary pumps with the largest flow rate, namely 2.0–3.7 nL s−1. A larger
flow resistance (R5) slowed down the flow rate to 0.6–0.7 nL s−1. By further
increasing the flow resistance (R9, R13), flow rates down to 0.2–0.4 nL s−1
could be achieved. Irrespectively of the preceding flow-resistance area, the
capillary pump with the smallest characteristic dimension of 15 µm exhibits
an experimental flow rate that is significantly smaller than expected from
the calculations. For the other CSs, experimental results fit the predicted
flow rates with a deviation of ∼10 %. Large flow resistances (R9, R13) can
predominate the flow rate, whereas the capillary pump determines the flow
rate when flow resistances are small (R1), see CS 15_R1 and CS 250_R1 in
Fig. 5.3. Although the internal structure of the capillary pump seems to be
less important for the flow rate than the flow resistance, it can be relevant to
ensure a proper filling as we will show next.
Time series of typical filling fronts of coloured water in various types of CSs
are shown in Fig. 5.4. The liquid fills the capillary pumps from the left to the
right. The exact shape of the filling front depends on the total flow resistance
and the type of capillary pump. A low flow resistance (R1, R5) in front of a
“symmetric line”-type capillary pump results in a filling front that is parallel
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(a)Low flow resistance in front of the capillary pump
(b) High flow resistance in front of the capillary pump
(c) Orientation of the filling front
1 2 3 4 5 6 7 8
1 2 3 4
5 6 7 8
1 2
3 4
Figure 5.4. Time series of optical micrographs showing the typical filling fronts of coloured
water in various types of capillary pumps. Liquid flows from left to right. (a) Flat filling
front in a capillary pump that is preceded by a low-flow resistor and corresponding scheme
showing how the water menisci (plain lines) progress from structure to structure (dashed
arrows). (b) Capillary pump preceded by a high-flow resistor that has a meandering filling
front. Such a capillary pump is designed to minimize the risk of entrapping air. (c) Example
of a capillary pump designed to control the shape and orientation of the filling fronts in the
capillary pump. The scale bars are 500 µm. These results are also available as videos [115].
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to the microstructures, Fig. 5.4a. The liquid spreads preferably along the
edge of the capillary pump into the next row of microstructures and is then
drawn by the slightly higher capillary pressure into the space between two
parallel lines, and fills the entire width of the capillary pump. This overall
straight filling front moves consistently along the main axis of the capillary
pump. In Fig. 5.4b the capillary pump has the same capillary pressure as
in Fig. 5.4a but the flow resistance is larger (R13), which reduces the flow
rate and changes the filling behaviour. Here spreading of liquid along the
edge of the capillary pump predominates. In the case of a sealed capillary
pump, such a filling behaviour increases the risk of incomplete filling and
enclosing air. This risk is minimized when using the “symmetric line”-type of
capillary pumps in which two filling fronts of liquid converge from the edges
of the capillary pump toward its centre without entrapping air. For small
characteristic dimensions (15 µm) in the capillary pump, Fig. 5.4c, the filling
line is rotated by 45◦ compare with the large structures in Fig. 5.4a. The
capillary pump shown in Fig. 5.4c has two main parts, namely, of a triangular
entrance and a rectangular main body. Spreading of liquid along the edges
of the capillary pump is slowed down in the entrance of the capillary pump
because the entrance sidewalls are indented. In the rectangular part of the
capillary pump, the microstructures are parallel to the sidewalls and these
walls are therefore not indented. Accordingly, the microstructures vicinal
to the sidewalls are placed 25 µm instead of 15 µm away from the walls to
reduce the capillary pressure in this region and to prevent undesired spreading
of liquid along the peripheral walls.
5.3.3. Serial connection of capillary pumps
Biological assays typically comprise multiple incubation and rinsing steps,
which can differ in duration. Because liquids in CSs flow in a laminar manner,
a brief rinsing step can be an efficient way to remove a preceding liquid from
a reaction chamber [33]. In contrast, the time needed to capture antigens
from solution or to bind detection antibodies to a surface-immobilized antigen
necessitate minutes [34]. Matching the flow rates during an assay to the
optimal durations of individual steps is desirable to shorten the time to result
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when using microfluidic systems, Chapter 2, [34].
A sequence of steps can be optimized using a capillary pump with multiple
zones, each generating a slightly different flow rate. It is easy to design a CS
in which a first capillary pump is followed by a second, slower one because
the high flow resistance of the second capillary pump does not affect the fill-
ing of the first capillary pump. The reverse case is more challenging for two
reasons. First, the filling behaviour of the liquid in the capillary pumps must
be carefully controlled to prevent the first (slow) capillary pump from being
bypassed. The second challenge for accelerating a liquid in a CS using serial
capillary pumps is the additive effect of flow resistances of serial microfluidic
elements. Bypassing, as has been shown above, occurs preferentially along the
peripheral edges of the capillary pump and might lead to an only partial filling
of the first capillary pump. The risk of bypassing can be greatly reduced by
selecting a capillary pump having indented peripheral walls, Fig. 5.5. In addi-
tion, the liquid at the end of the first capillary pump can gradually be directed
to a single connexion channel using a series of hierarchical bridges, Fig. 5.5a.
Here, the capillary pressure in the successive bridges diminishes (in absolute
value) and favours the complete filling of the small bridges over that of the
larger ones. The geometry of the junction between smaller and larger bridges
also helps pinning a liquid that fills a bridge from only one side until the liquid
has also filled the second branch. We found such hierarchical structures very
efficient for the CSs designed here. In addition, these structures have a rela-
tively small footprint. The increase in resistance of serial capillary pumps can
be compensated by augmenting the capillary pressure in the second capillary
pump compared with that in the first one. The serial capillary pumps shown
in Fig. 5.5b are connected via hierarchical bridges, do not entrap air, are not
bypassed by the spreading of liquid along the capillary pump edges, and the
second capillary pump generates a flow rate that is about twice as fast as the
first one.
5.4. Conclusions
The work presented here enhances the capabilities of autonomous CSs by
showing how to program their filling properties. The possibility to slow down
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(a)Bubble-free merging of flow streams
(b) Slow and fast serial capillary pumps
1 2 3
4 5 6
Figure 5.5. Optical micrographs showing (a) the consolidation of liquid streams at the end
of a capillary pump to prevent entrapping air or incomplete filling of a capillary pump, and
(b) a liquid moving from a completely filled, slow pump to a second faster pump. The inset
shows the same region observed a few seconds later when liquid starts filling the second
pump. The scale bars are 500 µm.
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or even temporarily stop the flow of liquid in a CS makes it possible, for ex-
ample, to fill a reaction chamber, perform an incubation step or enzymatic
assay, and flush the reactants and products for a next test in the same CS.
Enzyme-linked immunosorbent assays as well as other types of assay could in
principle be implemented on CSs using appropriate types of capillary pumps.
These CSs would certainly lead to sensitive and versatile platforms for point-
of-care testing [116]. Here, we studied capillary pumps in combination with
flow resistances, in which the capillary pressure was defined solely by the ge-
ometry. Such CSs can also have tailored surface chemistry [117] to further
enhance their flow behaviour or to add new functionalities such as hydropho-
bic valves and metering channels. Other functions that can be added to CSs
are filters for cells or particles, mixers, chambers with immobilized cells, and
surface-immobilized binding sites for analytes. The small form factor of CSs,
their simplicity in term of utilization, and the possibility to tailor their hy-
drodynamic properties using advanced capillary pumps may help to promote
their use for a large number of applications in which miniaturization provides
a benefit to performing biological assays.
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6. High-performance
Immunoassays Based on
Through-stencil Patterned
Antibodies and Capillary
Systems
Autonomous capillary systems (CSs) are self-powered microfluidics that can
be used for detecting multiple analytes in sub-microliter volume of sam-
ple, within minutes and with picomolar sensitivity, i.e. CSs enable high-
performance immunoassays. We present a simple method to pattern capture
antibodies (cAbs) on PDMS with high accuracy and in a manner compatible
with mass fabrication for use with CSs.1 Capture antibodies are patterned in
dense lines of up to 8 lines per millimeter of PDMS and used with CSs that
have been optimized for convenient handling, pipetting of solutions, pumping
of liquids such as human blood serum, and visualization of signals for fluores-
cence immunoassays. The detection of CRP with a sensitivity of 0.9 ng mL−1
(7.8 pM), in 1 µL of CRP-spiked human serum, within 11 minutes, using four
pipetting steps and a total volume of sample and reagents of 1.35 µL exem-
plifies the high-performances that can be achieved using this approach and
an otherwise conventional surface sandwich fluorescence immunoassay. This
method is simple and flexible and should therefore be applicable to a large
number of immunoassays.
1J. Ziegler, M. Zimmermann, P. Hunziker, E. Delamarche, High-performance immunoas-
says based on through-stencil patterned antibodies and capillary systems, first published
in Analytical Chemistry, 80, 1763–1769, 2008.
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6.1. Introduction
Immunoassays are widely used for diagnostics, research in life sciences, therapy
monitoring, environmental monitoring, and food safety [3]. These assays rely
on the specific interaction between antigens and antibodies to detect analytes
(antigens or antibodies) of interest in body fluids or other samples. Even for a
single type of application, the requirements for having informative and efficient
immunoassays can vary strongly. There is for example a notable difference
between platforms used for portable immunoassays done near a patient and
for a clinical analyzer from the central laboratory of a hospital. The first
platform must be simple to use and provides results within minutes whereas
a clinical analyzer typically runs a large number of possible tests and can
process samples (i.e. filtration, dilution, thermal treatment, spinning, etc.) to
optimize the sensitivity and accuracy of the test. Immunoassays, that are used
for research in life sciences are usually more specialized and customized than
for diagnostics. The signal of the assay can be based on radioactivity, light
(emitted or absorbed), a current, [118] fluorescence, or even changes in the
index of refraction [119] or mass of a sensing surface [120]. These assays
comprise numerous incubation and rinsing steps with volumes of solution
ranging from a microliter to hundreds of microliters. These steps can last
for a few seconds, for example, when rinsing or adding reagents, to hours, for
example for ligand-receptor binding reactions for high-sensitivity assays. The
diversity of platforms, [121] formats, and steps performed for immunoassays
in research suggests that new platforms should be versatile and flexible in the
number of steps and volumes of solutions, they can accommodate.
We pioneered the concepts of microfluidic networks and then CSs with the
goal of providing convenient platforms for high-performance immunoassays
[49]. Key to these concepts is the use of a PDMS substrate patterned with
receptors for analytes that can reversibly seal microfluidic structures [78]. The
microfluidic structures are accurately prepared by means of microfabrication
using Si wafers or in plastics using replication techniques. CSs extend mi-
crofluidic networks by implementing a more precise control over filling behav-
ior of liquids entering the microstructures [33]. They typically have loading
pads inside which reagents and samples are pipetted, reaction chambers cov-
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ered by PDMS, and capillary pumps. Valves and flow resistances can also be
added to reduce evaporation of liquid, meter liquid, or delay the progression
of a liquid in the different parts of the CS, Chapter 5, [33]. Importantly,
the geometry and wetting properties of the microstructures encode a capil-
lary pressure in the various parts of the CSs, which permits drawing a desired
amount of liquid in a CS with a controlled flow rate without requiring actuated
pumping systems. The merit of CSs for immunoassays is the possibility to
detect rapidly multiple analytes in samples smaller than 1 µL in volume [34].
Here, the patterning of cAbs on PDMS plays a critical role by providing well-
defined areas where analytes are captured. These areas, which are typically
a few tens of micrometers in lateral dimensions, help limiting the depletion
of analytes [29] and can be spaced so as to provide many contiguous signals
and controls, which is useful for the combinatorial screening of analytes, [35]
imaging data in one step, and achieving assays with small intra-assay vari-
ations [34]. These assays, called “micromosaic immunoassays”, utilize two
microfluidic chips for patterning cAbs and dispensing samples [14].
We present in this chapter a method for accurately patterning Abs on PDMS
using stencils that fit well with improved CSs for achieving high-performance
immunoassays in a flexible manner. We first describe the functions of the CSs
for immunoassays and the use of the stencils for delivering Abs to a PDMS
surface, and then assess the characteristics of sandwich fluorescence surface
immunoassays. These immunoassays were performed with stencil-deposited
cAbs, the new CSs, and human serum spiked with CRP. CRP is a protein
rapidly synthesized by the liver in response to many conditions including
infection, inflammation, and cardiovascular diseases [122, 123].
6.2. Experimental Section
6.2.1. Reagents and Proteins
Solutions of PBS (tablets P4417, Sigma) and BSA (Sigma) were reconsti-
tuted in ultra pure water (Millipore Simplicity 185, Bedford MA) and filtered
prior to use with a 0.20 µm syringe filter (Sartorius, Epsom UK). Solutions
of alkanethiols were prepared in ethanol (puriss. = 99.8 %, Fluka) using
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thiolated poly(ethyleneglycol) (HS-PEG) (CH3O-(CH2CH2O)n-SH, molecu-
lar weight of 750 g mol−1, Rapp Polymere GmbH, Tübingen, Germany) and
hexadecane thiol (HDT) (HS-(CH2)15-CH3, Fluka). PDMS prepolymers (Syl-
gard 184, Dow Corning, Midland MI) were mixed at a ratio of 1:10 using a
DOPAG mixer (Cham, Switzerland), poured onto planar polystyrene Petri-
dishes (Greiner BioOne), and cured over night in a oven at 60 ◦C. The cured
3-mm-thick layer of PDMS was cut into 8× 8 mm2 pieces. Abs were patterned
on the surface of the PDMS that faced the Petri-dish.
Lyophilized goat anti-rabbit immunoglobulin G (IgG) (R2004, Sigma-
Aldrich) and rabbit anti-guinea pig IgG tetramethylrhodamine isothiocyanate
(TRITC)-labelled (T7153, Sigma-Aldrich) were reconstituted in PBS at con-
centrations of 125 and 250 µg mL−1, respectively. Human CRP (8C72), anti-
CRP (4C28-C2, 4C28-C6), anti-CRP-FITC (4C28F-C6) and human CRP free
serum (8CFS) were bought from HyTest (Turku, Finland) and diluted in PBS.
Human CRP-free serum was spiked with human CRP to the desired CRP
concentration. The anti-CRP-C6 Abs were labelled using an Alexa Fluor 647
labeling kit (Alexa Fluor 647 Monoclonal Antibody Labelling Kit, Molecular
Probes). The number of fluorophores per protein was measured to be four
using an Eppendorf BioPhotometer.
6.2.2. Handling of Microfluidic CS and Templates
The microfluidic CSs and the stencil templates were etched in Si using pho-
tolithography and deep reactive ion etching. The CSs were sputtered with Au
and diced to yield individual microfluidic chips having each 6 CSs each.
Prior to each use, the microfluidic chips were cleaned in an UV-ozone reactor
(UV-Ozone Photoreactor PR-100, Ultra-Violet Products, Upland, CA) during
60 min. A planar PDMS stamp having the size of a microfluidic chip was inked
with a 2 mM solution of HDT in ethanol for 30 s, rinsed with ethanol, and
dried under a stream of N2. The PDMS stamp was applied manually to the
chip for 30 s to make its top surface hydrophobic. The chip was then covered
with a 2 mM solution of HS-PEG in ethanol for 30 s, rinsed with ethanol,
and dried under a stream of N2 to render the CSs wettable and the surfaces
protein-repellent. The derivatized chips were stored in a dry environment and
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typically used within 6 h.
The Si wafers with the stencils were diced into 12 × 12 mm2 individual
templates having 16 or 24 stencils. Each stencil comprises a loading pad
connected to a 2-mm-long line. The templates were cleaned in O2-plasma
(Tepla Microwave-Plasma System 100, PVA Tepla, Asslar Germany) during
2 min at 200 W and 0.7 Torr before they were placed on the PDMS block.
The stencils were filled with a solution of cAbs for a 15-min-long deposition
of cAb on PDMS at room temperature. The stencils in contact with PDMS
were rinsed under a stream of PBS and ultra pure water. The PDMS surface
was separated from the stencil using tweezers, exposed to a blocking solution
of BSA for 15 min, rinsed with PBS, ultra pure water, and dried under a
stream of N2. The templates were rinsed and cleaned in an O2-plasma before
reuse.
The PDMS block was placed on the CSs in such a way that the lines of cAbs
were oriented perpendicularly to the reaction chambers of the CSs. A non-
patterned block of PDMS was used to seal the capillary pumps. Immunoassays
were performed by pipetting the solution of analyte into the loading pads of
the CSs, followed by a solution for rinsing, and a solution containing detec-
tion antibodies (dAbs). CRP-free human serum was then placed around the
PDMS substrate, which was removed from the CSs. The PDMS was rinsed
under a stream of PBS and ultra pure water, dried under a stream of N2 and
imaged. Fluorescence micrographs were obtained using a fluorescence micro-
scope (Eclipse 90i, Nikon, Japan), which was equipped with a 100 W halogen
lamp for excitation, and a digital camera (DS-1QM, Nikon) cooled to -30 ◦C
for imaging. Fluorescence micrographs were analyzed using the software NIS-
Elements (Nikon). After the experiments, the microfluidic chips were rinsed
with PBS, ultra pure water and ethanol, dried under a stream of N2, and
cleaned again in the UV-ozone reactor.
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Figure 6.1. Photograph of a Au-coated silicon microfluidic chip having six independent
CSs. Up to 6 independent surface immunoassays can be performed using such a chip.
Assays are performed by successively loading samples and reagents in the loading pads and
capturing analytes flowing in the reaction chambers using cAbs, which are patterned on a
sealing block of PDMS.
6.3. Results and Discussion
6.3.1. Capillary Systems
Figure 6.1 shows a microfluidic chip having six independent CSs with their re-
action chambers sealed with a block of PDMS. All structures of the CSs have
a depth of 180 µm, except for the reaction chambers, which are 20 µm deep.
A depth of 180 µm enables loading pads and sealed capillary pumps to hold
a total volume of 2 µL without requiring too large a footprint on the chip.
When 2 µL of solution are pipetted into a loading pad, most of the solution
protrudes outside of the pad without spreading toward adjacent pads because
the top part of the chip is covered with a hydrophobic self-assembled mono-
layer. These pads are approximately twice as large as those of the previous
CSs [33] to ease the loading of solutions using manual micropipetting. The
depth of the reaction chambers provides a good compromise between having
an efficient transport of analytes to the capture sites, Chapter 2, keeping the
hydraulic resistance of the reaction chamber low, and preventing the collapse
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Average flow rates in the Sample Reaction chamber
reaction chambers viscosity 20 µm deep 30 µm deep
/ mPa s / nL s−1 CV /% / nL s−1 CV /%
Water 1 1.9 4.7 4.2 4.8
PBS + 1% BSA 1 1.9 5.0 4.0 3.4
Solution of 20% hum. al-
bumin
4 0.5 12.0 1.5 11.9
Table 6.1. Characteristic flow rates of samples filling CSs and corresponding coefficients
of variation (CV).
of the PDMS into the chamber [124]. The reaction chambers are 30 µm wide,
9 mm long, and are separated from each other by 120 µm. Their length per-
mits the convenient manual placement of a block of PDMS having numerous
lines (> 20) of cAbs and their spacing allows having six rows of signals per
millimeter. Grouping the reaction chambers in the center of the chip facil-
itates imaging the results of assays because the fluorescence signals on the
surface of PDMS can be acquired in one imaging step [34]. The total volume
of 2 µL of the capillary pumps was selected based on previous work, in which
600 nL of sample were used for high sensitivity assays, [34] and based on the
maximum volume of dAbs and rinsing solution estimated to be necessary for
completing the assay. The pumps have a vent to prevent the entrapment of
air. The use of large pads and pumps and the grouping of reaction chambers
in the middle of the chip make the CSs asymmetric: CSs at the periphery of
the chip have longer distances between pads, pumps, and reaction chambers.
For this reason, meandering channels are added to the inner pads on both
sides of the reaction chamber to equalize the hydraulic resistance of all CSs.
A sample added to a loading pad of a CS flows through the reaction chamber
and moves into the capillary pump at a flow rate depending in part on the
surface tension and viscosity of the sample, Table 6.1. Water and a solution of
1 % BSA in PBS, which has a similar viscosity as human serum (1 mPa s), flow
at 1.9 nL s−1 with variations ±5 % through CSs having 20 µm deep reaction
chambers. Reducing the hydraulic resistance of the CSs by using 30 µm deep
reaction chambers increases the flow rate to 4.2 nL s−1 for water and 4 nL s−1
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for PBS containing 1 % BSA. Blood or blood plasma, which might be used
in point-of-care applications, have higher viscosities than serum. The blood
viscosity depends on the hematocrit and can amount to 3 to 8 times the
viscosity of water, with typical values being 3 to 4 [125]. As blood is a non-
Newtonian liquid, the viscosity therefore depends also on its velocity [126].
The viscosity of plasma is ∼1.8× higher than that of water. We chose a
solution of 20 % human albumin as a model liquid to measure the flow rate of
a liquid having a viscosity of 4 mPa s in CSs. As expected, such a liquid flows
slower than less viscous solutions with flow rates of 0.5 nL s−1 and 1.5 nL s−1
in CSs having 20 µm deep and 30 µm deep reaction chambers, respectively.
The coefficient of variation is ∼12 % in both cases, which might be improved
by optimizing the internal structures in the capillary pump to have finer and
more continuous structures. In the experiments described next, CSs having
20 µm deep reaction chambers are used, in which 0.9 µL of human serum flow
within ∼8 min.
6.3.2. Patterning of Capture Antibodies Through Stencils
Figure 6.2 shows a template that is used to localize antibodies to specific areas
of a PDMS surface as well as fluorescence images of the resulting patterns.
The template was microfabricated in Si and has zones with four stencils. The
template can readily be rendered hydrophilic or cleaned for reuse by using an
O2-based plasma. The template is placed manually on a block of PDMS, and
the conformal contact occurring between the PDMS and the template seals the
stencils. The stencils are accessible from above and can be filled individually
by manual pipetting. The pads and stencils are laid out in such a way as to
ease the addressing of each pad while keeping the stencils grouped as much as
possible to keep the assay signals as contiguous as possible. Using a pitch of
1 mm for the loading pads and keeping the solution of antibody solution that is
pipetted into the pads to values smaller than 0.3 µL help prevent pad overflow
and crosstalk when pipetting manually. We found that a deposition time of
15 min was sufficient to saturate the PDMS surface with a layer of Abs using a
125 µg mL−1 solution of Abs in PBS. The filled template was kept in a humid
environment during deposition to prevent evaporation of solution from the
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(a)Preparation of cAb on PDMS
(b) Patterned antibodies on PDMS
150 µm1 mm
5 mm
Figure 6.2. Local delivery of Abs to PDMS areas using microfabricated stencils. (a) The
2-mm-long stencils of a silicon template can be filled individually with a solution of Abs,
rinsed under a stream of PBS and deionised water. The PDMS is then separated from
the template under a blocking solution of BSA and dried. (b) Fluorescence micrograph
showing the accurate delivery of TRITC-labeled Abs through stencils onto a PDMS surface
homogeneously covered with cAbs.
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stencils. All stencils were rinsed for a few seconds using a flexible dispensing
bottle filled with PBS and with the jet of PBS being in the direction of the
stencils, Fig. 6.2a. The template adhered well to the PDMS, even during
intense rinsing involving multiple steps. The template was separated from
PDMS in a BSA bath to quickly cover any area of PDMS left free of Abs with
BSA. The fluorescence images in Fig. 6.2b show an example of delivering
Abs locally to PDMS areas using 60 µm wide stencils. In this case, cAbs
(anti-rabbit IgGs) have been homogeneously applied from solution to PDMS
and 0.3 µL aliquots of TRITC-labeled rabbit IgGs were locally provided in
each stencil. The homogenous fluorescence signals observed in the inner area
of the template (dashed rectangle in Fig. 6.2b) underline the homogeneous,
local delivery of Abs to the PDMS surface. Having a pad at the beginning
of each stencil not only facilitates the addressing of the stencil but also helps
localize imperfections (drying artifacts, entrapment of air bubble) away from
the area used for the assay.
Stencils can greatly vary in size and be several hundreds micrometer wide,
[127] a few micrometers in diameter, [128, 129] or even just 100 nm in size [130].
Here, we looked for stencils that were (i) easy to microfabricate even with
micrometer accuracy, (ii) small enough to enable the delivery of approximately
6 to 10 solutions of proteins per millimeter across capture areas and to allow
the use of sub-microliter volumes of protein solution, and (iii) made from
a material that can withstand strong oxidizing conditions so that cleaning
them and removing proteins from the template would be easy using ozone,
oxidative plasmas, or oxidants in solution. The length of the stencils provides
the possibility of patterning long lines of cAbs on PDMS, thereby preventing
issues involved in aligning the reaction chambers of CSs with the patterned
cAbs. The width of the stencils defines one lateral dimension of the mosaic of
fluorescence signals. We were not able to fill stencils individually by hand if
their pads had a pitch of 0.6 mm. Pipetting robots can in principle be used
for filling higher-density stencils and/or preparing PDMS substrates in mass
for miniaturized immunoassays. In the remainder of the chapter, cAbs for
CRP are patterned onto PDMS using 16 stencils as shown in Fig. 6.2a, with
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a pitch of 1 mm between pads and 120 to 270 µm wide stencils. These assays
have a potential maximum of 96 test sites when combined with a microfluidic
chip having six independent reaction chambers.
6.3.3. Immunoassays for c-reactive protein in capilary
systems
A first series of immunoassays was performed in CSs using human serum
spiked with 0.1 µg mL−1 CRP to determine the homogeneity of the fluores-
cence intensity in adjacent capture areas and CSs, Fig. 6.3. This immunoas-
say was also developed with the goal of using minute volumes of solutions
and brief incubation times. A volume of 1 µL of CRP-spiked human serum
was added in each pad of the CSs, except in CS No. 2, in which CRP-free
human serum was loaded to provide a control. After a quick rinsing step
with CRP-free human serum, 0.25 µL of a solution of Alexa-647 labeled dAbs
was flown through the CS for 2 min followed by a second brief rinsing step,
Fig. 6.3a. After 11 min the assay was finished and the block of PDMS sepa-
rated from the CSs in the presence of human serum. The PDMS surface was
rinsed, dried, and the fluorescent signals were imaged. A fluorescence image
of a block of PDMS having three rows of cAbs (A, B, C, deposited using the
stencils) that are crossed by six CSs (1 - 6) is shown in Fig. 6.3b. CRP in
the CSs passed over rows A, B, and then C. The 15 zones of signal shown in
Fig. 6.3b are accurate rectangles, having a width of 30 µm (corresponding to
the width of the reaction chamber in the CS) and a length of 120 µm (cor-
responding to the width of the stencils). No signal was generated in CS 2 or
outside the areas of PDMS, where no cAbs had been patterned, as expected.
A detailed comparison of the fluorescence intensities of the individual areas,
Fig. 6.3c, reveals that corresponding areas A1-A6, B1-B6 and C1-C6 in in-
dependent CSs have similar intensities, whereas the areas A, B, and C in the
same CS have decreasing intensities. The first areas of cAbs (A) that were
passed by CRP exhibit a larger fluorescence intensity than subsequent areas
(B, C). This decrease of the fluorescence intensity originates from a slight
depletion of CRP analyte in the reaction chamber during the capture step.
In Fig. 6.4, 14 lines of cAbs and 5 CSs were used, and CRP was omitted in
one of the CSs to provide a control. An intensity profile of the fluorescence
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Figure 6.3. Fluorescence surface immunoassays for CRP performed in CSs using cAbs
patterned on PDMS using a stencil template. (a) The immunoassay comprises four pipet-
ting steps for incubation of the analyte, rinsing of non-captured analytes, binding dAbs to
captured analytes, and rinsing excess dAbs. (b) The CSs were sealed with PDMS from
the beginning of the reaction chamber to the end of the capillary pumps. The PDMS
was patterned with lines of one type of cAbs (CRP-C2, 125 µg mL−1) which are cross-
ing the reaction chambers of the CSs. The optical micrograph shows the fluorescence
signal of Alexa-647-labeled dAbs (CRP-C6, 250 µg mL−1) after 5 identical assays (CRP,
0.1 µg mL−1) were performed in each CS except in channel 2, in which the analyte was free
of CRP. (c) The bar chart shows the mean fluorescence intensity of the signals shown in
(b) with the standard deviation (not to scale).
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signal corresponding to a concentration of CRP of 1 µg mL−1 is shown in Fig.
6.4b. The fluorescence intensity of the signals slowly decreases from the first
area of cAbs to the last one, and it decreases faster along one area of cAb.
This reflects the depletion of CRP along the reaction chamber, but also the
enrichment in CRP of the depleted boundary layer during the 0.22 s it takes
the sample to reach the next capture area. After the fourth capture area, the
mean fluorescence signals of the remaining areas are equal, which suggests
that the depletion layer in proximity to the surface has grown and a steady
state has been reached between the diffusive and convective mass transport
of CRP to the cAbs areas and the binding of CRP to the cAbs.
Figure 6.5 shows a micromosaic immunoassay for CRP using CSs and
stencil-deposited cAbs that results from using three lines of cAbs (120 µm
wide stencils) and six CSs (30 µm wide reaction chambers). The flow rate in
this assay was controlled entirely by the capillary pump, and no particular
precaution had to be taken to prevent evaporation of the liquids added to the
pads. The fluorescence intensity of the signals on each row was averaged and
used to make a reference curve of for the assay. A total of six independent
experiments were performed to obtain the reference curve shown in Fig. 6.5b.
The calculated sensitivity of the assay (smallest concentration more than three
times larger than the standard deviation of the zero analyte concentration)
is 0.9 ng mL−1, i.e. 7.8 pM. The coefficients of variation are < 8 % for con-
centrations ≤ 0.1 µg mL−1 and 12 to 15 % for smaller concentrations. The
sensitivity of the CRP assay shown here is impressive considering that 1 µL
of sample for multiple test areas, 11 min, and a conventional immunoassay
format were used. This assay is notably fast, sensitive, and economical of
sample compared with commercially available ELISA assays for CRP [131].
The sensitivity might be further improved by employing signal amplification
strategies similar to the work by Hosokawa et al. [132] although this would be
at the expense of making the assays longer, using more reagents, and adding
numerous pipetting steps. PDMS has a refractive index of 1.47, is transparent
and has a low autofluorescence for wavelengths below 600 nm [34]. It is there-
fore possible to measure the fluorescent signals of the mosaic directly through
PDMS without having to remove PDMS from the CSs and drying the PDMS
surface. Preliminary experiments showed similar relative intensity of fluores-
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Figure 6.5. Micromosaic immunoassay and reference curve for CRP in human serum. (a)
Optical micrograph showing a mosaic of fluorescence signals corresponding to the detection
of CRP using cAbs (125 µg mL−1 in PBS) deposited onto PDMS using stencils. CRP
spiked CRP-free human serum and FITC labelled dAbs (250 µg mL−1 in CRP-free human
serum) were provided horizontally in independent CSs. The CRP concentration was 10 (top
row), 0, 3, 1, 0.3, and 0.1 µg mL−1. Each concentration of CRP results as a fluorescence
intensity as can be seen in the vertical graph on the left. The horizontal intensity profile
shows fluorescence intensity of a particular CRP concentration over different lines of cAbs.
(b) The fluorescence intensities obtained from assays done with different concentrations of
CRP (`) and their coefficient of variation (a) are plotted. The fluorescence intensities are
fitted with a sigmoidal curve (-). Error bars correspond to the standard deviation. This
assay has a calculated sensitivity of 0.9 ng mL−1. The line (· · ·) is provided as a guide for
the eye. 91
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cence but less sharp images probably due to optical effects (data not shown),
see Chapter 7. The in situ detection of CRP, and potentially many other
markers, is nevertheless promising for further simplifying the use of CSs and
encoding immunoassays on microfluidic chips for point-of-care diagnostics.
6.4. Conclusions
Stencil-based patterning of cAbs on a PDMS substrate is a convenient method
to immobilize cAbs on PDMS in a manner that should be compatible with
techniques used for the mass fabrication of diagnostic devices. We regard the
accurate patterning of cAbs as key to achieving high-performance surface im-
munoassays that do not require complex or cumbersome peripherals, surface
engineering, or signal-amplification methods. By following the examples pro-
vided here for stencils and CSs, we suggest that users interested in detecting
antigens in microliters or less of samples should easily be able to set their own
assays using standard reagents, pipetting methods, and fluorescence readers.
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for One-step Immunoassays
Autonomous capillary systems (CSs), in which liquids are transported owing
to capillary forces, have been previously used to perform fast and sensitive
multi-step immunoassays using minute volumes of analyte. CSs for diagnostic
applications have different requirements than CSs that are used as a research
tool in life sciences, where a high flexibility and performance prevail over ease
of use and portability. In this chapter,1 a proof-of-concept for one-step im-
munoassays based on CSs is demonstrated. This proof-of-concept is based
on preloading detection antibodies (dAbs) on the flow path of analytes and
redissolving these antibodies to form dAb-analyte complexes, which can be
detected using fluorescence downstream on accurately patterned capture anti-
bodies (cAbs). A user therefore only needs to load a sample at the beginning
of a CS and obtains the result of the assay using a conventional fluorescence
microscope or scanner. As an example, c-reactive protein (CRP) was detected
in human serum at clinical concentrations within 10 minutes and using only
2 µL of sample.
7.1. Introduction
Immunoassays are widely used for detecting analytes (antigens) for diagnostics
[3], environmental monitoring [133], therapy monitoring [134], research in the
life sciences and food safety [135], for example. Platforms for immunoassays
differ widely, from clinical analyzers ran by expert staff to lateral flow tests
used at home for pregnancy testing [3]. Novel platforms for immunoassays
1M. Zimmermann, P. Hunziker, E. Delamarche, Autonomous capillary system for one-step
immunoassays, first published in Biomedical Microdevices, 11, 1–8, 2009.
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are emerging with the advent of miniaturization and microfluidics in which
multiple functions, such as metering and preprocessing of a sample, analysis,
recording and calibration of the results, can all be done on a portable plat-
form [136, 137]. We are interested in applying the concept of autonomous
CS to the detection of disease markers for point-of-care testing of patients,
with the ultimate goal of detecting a few related disease markers in less than
approximately 10 min, with 2 µL of sample or less, and with only one step
of handling. Another important goal is to devise a flexible approach where
the volume of sample, the number of analytes to be detected, and the flow
conditions of the assays can easily be adjusted by only a minor redesign of
the CS.
Ideally, for point-of-care diagnostics, the handling of a CS should be as sim-
ple as it is for pregnancy tests [138] or for glucose measurements for diabetes
management [139]. Immunoassays that provide results within minutes outside
of a clinical laboratory are based on lateral-flow, flow-through, agglutination,
or solid phase technology. Lateral-flow tests, also called immunochromato-
graphic strip tests, are used for qualitative or semi-quantitative detection of
analytes in a body fluid. Lateral-flow tests only require the addition of the
sample. With flow-through tests, the analytes and solutions for washing and
detection can be flown sequentially through a porous membrane or, in mod-
ern tests, through a channel. The latest versions of such flow-through tests all
have the reagents integrated on-chip [140]. In agglutination tests, the sample
is placed on a substrate and analytes are detected following the binding of an-
alytes with colored particles having analyte-specific receptors. Point-of-care
agglutination tests can therefore hardly be miniaturized nor can they have in-
tegrated reagents. Solid phase tests have cAbs immobilised on a non-porous
substrate, are dipped into the analyte, and then into solutions for washing
and detection. Solid-phase tests in general have less sensitivity for detection
of antigens than lateral-flow tests do. All of the tests described provide fast,
qualitative or semi-quantitative measurements of analytes in resource-poor
environments at a moderate price.
Testing of multiple parameters from the same drop of sample might be desir-
able for precise diagnostic of myocardial infarction, for instance, where cardiac
troponin, CK-MB, and myoglobin are of interest [32]. These three markers
94
7.2. The One-step Concept
can be qualitatively measured on a single chip, but the chip in fact has two
qualitative lateral-flow tests integrated into a single chip having two openings
for the blood sample, both of which need to be filled [141]. Quantitative flow-
through assays can be performed on-chip for each of the cardiac markers in
combination with portable reader instruments [8, 9]. The chips are assembled
using a filter membrane for filtering cells from the blood plasma in front of
a microfluidic channel and contain all the reagents. The reagents might be
embedded in the filter membrane [140] or in a cavity [142] from where the
reconstituted reagents are delivered within a certain time span. The markers
are detected in separate chips using gold-labelled immunochemistry assays [8],
or immunofluorescence assays [9]. Quantitative results are typically obtained
within 15 minutes from 150 µL of sample volume.
Other platforms in which immunoassays could be performed to detect mul-
tiple parameters and that might be suitable for point-of-care are the Lab-CD
[143], T-sensors [144, 145], and structurally programmable microfluidic sys-
tem (sPROMs) [104]. Lab-CDs are used in a CD-reader-type instrument, can
pre-process samples by centrifuging them, and can have multiple immunoas-
says integrated [143]. But complex and large rotational forces are critical
and make CDs that have biological reagents integrated difficult to fabricate.
T-sensors need to have active pumps for controlling the flow rates of liquids
[144], and sPROM devices have pressurized air chambers integrated that are
electrically activated for driving the liquid through the channel system [104].
7.2. The One-step Concept
A CS is an ensemble of connected microstructures in which one or multi-
ple liquids are displaced by means of capillary forces. Key elements of a CS
are the sample loading interface, the reaction chamber inside which the im-
munoassay takes place and the signal is measured, and the capillary pump,
which draws the sample at a programmed flow rate. CSs are well suited for
performing fluorescence sandwich surface immunoassays when they are sealed
with a PDMS cover onto which cAbs have been patterned. In this case, in-
dependent reaction chambers can be defined and/or different types of cAbs
can be used simultaneously for detecting several of antigens from one sam-
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ple. The small dimensions of the CS structures make paths for diffusions
short and rinsing steps very efficient owing to the laminar flow of liquids at
low-Reynolds-number flow.
The concept of a one-step immunoassay using a CS is sketched in Fig. 7.1.
The CS contains the pair of antibodies (cAbs and dAbs) needed to effect a
surface sandwich immunoassay. After loading a sample into a CS, the mi-
crostructures of the CS determine the flow rates and incubation times needed
to (i) dissolve dAbs and reconstitute them in solution, (ii) form the dAb-
analyte complexes, (iii) move and bind the dAb-analyte complexes to the
surface-immobilized cAbs, and (iv) rinse excess dAbs using some of the sam-
ple in which no dAbs dissolved. The fluorescence signal corresponding to the
cAb-analyte-dAb complex can then be measured using a fluorescence reader
or microscope. The assay time for such a one-step assay is predefined at the
time of manufacturing of the CS by defining the hydraulic resistance and wet-
ting properties of the structures. Some functional elements for preprocessing
the sample as well as reagents for control purposes can be added [140]. A
membrane for filtering cells and particulates can, for example, be stacked at
the beginning of the CS [146]. Alternatively, microstructures in the CS can
be used to filter samples such as blood [147]. The time needed for preprocess-
ing the sample, reconstituting the dried dAbs, and binding them to analyte
molecules in the sample are ideally kept short while the step of binding dAb-
analyte complexes to cAbs is kept sufficiently long to improve the sensitivity
of the assay.
7.3. Experimental
The microfluidic CSs were fabricated using photolithography, deep reactive
ion etching, and silicon wafers. The etched wafers were sputtered with 10 nm
Ti and 150 nm Au, and then diced to yield individual microfluidic chips each
having six independent CSs. The CSs are 180 µm deep, except the reaction
chambers, which are only 20 µm deep. The reconstitution chamber is a 60 µm
wide microchannel and large enough for 2 µL solution of proteins. We have
also fabricated shallow, 30 µm deep reconstitution chambers for 0.3 µL, but
unless indicated otherwise, the deep ones were used. The capillary pumps were
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Figure 7.1. Concept of a one-step assay using a microfluidic CS.
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designed for pumping 2 µL of liquid and have a vent to prevent compression
of air when the CSs are sealed. The reaction chambers were designed a few
millimeters away from the rest of the CS to allow the manual alignment of
2 mm long lines of capture antibodies on PDMS orthogonal to the reaction
chambers, as discussed in Chapter 6.
The Au surface was cleaned in a UV-ozone chamber (UV-Ozone Photoreac-
tor PR-100, Ultra-Violet Products, Upland, CA) for at least 20 min. PDMS
stamps (Sylgard-184, Dow Corning, Midland, MI) approximately as large as
the microfluidic chips were coated with a 2 mM ethanolic solution of hexade-
canethiol (52270, Fluka, Buchs, Switzerland) for 30 s, rinsed with ethanol,
and blown dry under a stream of N2. A UV-cleaned microfluidic chip was
then microcontact printed with the inked PDMS stamp for 30 s to make the
top Au surface of the chip hydrophobic. A 2 mM ethanolic solution of thi-
olated poly(ethylene glycol) (HS-PEG 12750-4, Rapp Polymere, Tübingen,
Germany) was placed on the microfluidic chip for 30 s to make the Au-coated
walls of the CSs hydrophilic. The microfluidic chips were rinsed with ethanol
and dried under a stream of N2.
Detection antibodies (CRP-C6, HyTest, Turku, Finland) labelled with
Alexa-647 (Labelling kit A-20186, Molecular Probes) were prepared in a
60 mM solution of D(+)-trehalose (90208, Fluka, Buchs, Switzerland) con-
taining 20 mg mL−1 L-phenylalanine (78020, Fluka). For quicker dissolution
and reconstitution of the lyophilisate, the solution of dAbs was diluted by
a factor of 2 for some experiments. Chips were either not sealed at all or
partially sealed with a 1–2 mm thick layer of cured PDMS. The solution was
pipetted into the six CSs of the microfluidic chip and, after it had flown in
the microchannels, immediately frozen at -18 ◦C or -196 ◦C. A Petri dish
was filled with dry ice (-78 ◦C) onto which the frozen microfluidic chips were
placed. The Petri dish was put into a second, larger Petri dish and loaded
into a freeze-dryer (Alpha 1-2, Martin Christ, Osterode am Harz, Germany).
Alternatively, the frozen chips were put on a metal block cooled to -18 ◦C.
Open CSs were freeze-dried for 24 h; sealed ones for 2–3 days. After taking the
box containing the chips out of the freeze-dryer, the box was sealed with tape
and left for at least 30 min until it reached room temperature. Microfluidic
chips were typically used within half a day after they had been taken out of
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the freeze-dryer. Freeze-dried dAbs were observed in a scanning electron mi-
croscope (SEM) (LEO 1550, LEO Electron Microscopy Inc., Thorwood, NY).
The PDMS on sealed CSs was removed prior loading the CSs into the SEM.
Some minor fractions of lyophilisate stuck to the PDMS and were pulled out
of the CSs.
Capture antibodies (CRP-C2, HyTest, Turku, Finland) were patterned as
2-mm-long lines on a layer of PDMS, which was cured in a Petri dish and
cut to the size of the microfluidic chips. The PDMS surface was then blocked
with bovine serum albumin (A7906, Sigma), rinsed with deionized water, dried
under a stream of N2, and stored in a dry Petri dish containing a dessicant
(CaCl2) until it was placed over the CSs of a microfluidic chip having freeze-
dried dAbs. The lines of cAbs on the PDMS surface were aligned orthogonally
to the reaction chambers of the CSs, and the entire CSs were sealed except
for the loading pads. The CSs were used within 1 h after sealing with PDMS.
Human serum spiked with CRP was pipetted into the loading pads. The
redissolution of the dAbs and reconstitution in the human serum was observed
using a fluorescence microscope (Eclipse 90i, Nikon, Tokyo, Japan), which was
equipped with a 100 W halogen lamp for fluorescence excitation and a digital
camera (DS-1QM, Nikon) for imaging. To prevent evaporation of the sample
from the loading pad, the chip was observed in a humidified chamber.
7.4. Results and Discussion
We focus in a first step on a method to deposit dAbs in a CS and to recon-
stitute them in a sample, and then verify that CRP, a non-specific marker
for inflammatory responses, [122] can be detected from human sera with a
clinically relevant sensitivity. Figure 7.2 shows the layout of a typical CS for
a one-step immunoassay. A main loading pad having a maximum capacity
of 2 µL starts the CS and is connected to a reconstitution chamber. This
chamber holds dAbs (in dry state) and is connected to (i) a reaction chamber
sealed with a PDMS slab having lines of cAbs and (ii) an overflow chamber,
which is connected to a secondary pad. The functional elements of this CS
have a defined capillary pressure Pi, and a liquid moves spontaneously from
a zone with a low capillary pressure (absolute value) to a zone of higher cap-
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illary pressure. A strategy for depositing dAbs in the flow path of the sample
is depicted in Fig. 7.2b. A solution containing dAbs is added to the secondary
pad, from where it flows preferentially through the reconstitution chamber to
some extent toward, but not into, the main pad because |P1|, |P2| < |P3|, |P4|.
The reconstitution chamber is the zone exerting the highest capillary pressure
and therefore fills preferentially at the expense of the other structures; it has
a total volume of 2 µL. The overflow chamber has the purpose of accommo-
dating the volume fraction of solution of dAbs that exceeds the volume of the
reconstitution chamber. This ensures having a controlled and reproducible
amount of dAbs preloaded into the reconstitution chamber of the CS. Only
proteins preloaded in the reconstitution chamber finally reach the reaction
chamber. The interplay between the reconstitution and the overflow chamber
acts as a metering unit, leading to an estimated accuracy of the aliquot of
dAbs, which will be reconstituted, of better than ±5 nL. The typical error of
±4 % or ±80 nL for micropipetting by hand a volume of 2 µL is in comparison
much larger. The reconstitution and the overflow chamber have the shape of
a meandering channel to minimize their footprint on the chip while keeping
flows laminar and preventing having structures with dead volumes.
A sample placed in the main pad flows through the reconstitution chamber,
where dAbs dissolve and bind to analytes, Fig. 7.2b. The dAb-analyte com-
plexes flow to the reaction chamber and bind to specific cAbs. Detection Abs
are in excess compared with the analyte molecules and reconstitute in only a
fraction of the volume of sample. Free dAbs are therefore rinsed away from
the zones with the cAbs, similarly to how immunoassays in lateral flow tests
are performed. An external fluorescence reader excites the fluorescent dyes
conjugated to the dAbs and measures the emitted fluorescence, which relates
to the concentration of analyte in the sample. The capillary pump at the
end of the CS holds at least 2 µL of liquid, determines the flow rate of most
of the liquid flowing through the CS, and has a venting structure at its end.
We found it convenient to load the solution of dAbs to the secondary pad to
determine the best conditions for depositing the dAbs to the chip (volume,
composition of the solution, and concentration of dAbs). The dAb solution
can also be added directly to the main pad. In this case, an overflow chamber
is required if the volume of the dAb solution exceeds the total volume of the
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Figure 7.2. (a) Scheme of a one-step CS. (b) Scheme showing the filling procedure and
metering of dAbs and sample, and the reconstitution and mixing of dAbs with sample. (c)
Optical micrographs of a microfluidic chip in Si having six one-step CSs, two of which (the
middle ones) have no overflow chamber and a very small reconstitution chamber. The chip
is 28 × 22 mm2 and is covered with Au, with the top surface beeing hydrophobic and the
inner surface of the microstructures being hydrophilic.
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Figure 7.3. SEM images (a), (b) and optical fluorescence micrographs (c), (d) of dAbs,
trehalose, and phenylalanine in microchannels of a reconstitution chamber that were frozen
(a) at -18 ◦C and (b) at -196 ◦C and freeze-dried. Detection antibodies as shown in (b) are
redissolved and reconstituted in human serum (c) 8.25 min and (d) 9 min after loading the
human serum into the loading pads of the CS.
microfluidic elements between the main pad and the reaction chamber. The
microfluidic chip shown in Fig. 7.2c possesses six independent CSs, four of
which have an overflow chamber and secondary pad, as sketched in Fig. 7.2a.
The meandering microchannels located before and after the reaction chambers
act as hydraulic resistors to give all CSs an equivalent hydraulic resistance.
The reaction chambers on this chip are microchannels with a crossection of
30 × 20 µm2 (width × depth) and a length of 9 mm. These microchannels
run parallel in a region of the chip where a PDMS block having lines of cAbs
would normally be present during an assay.
7.4.1. Predeposition and reconstitution of labelled
detection antibodies
Besides the amount of dAbs preloaded on the CS, the volume of sample in
which the dAbs reconstitute is key for obtaining reproducible and sensitive
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assays. Figure 7.3 shows a lyophilisate containing dAbs that was dried in a CS
and the reconstitution of dAbs in a stream of human serum advancing in the
reconstitution chamber. The dAbs were freeze-dried in a matrix of phenylala-
nine and trehalose, which is frequently used for preserving the activity of dried
proteins for months [148, 149]. Phenylalanine crystalizes when it freezes [150]
and forms a scaffold covered by a layer of trehalose [148]. The reasons for the
preservation effect of trehalose and other sugars are still beeing discussed in
literature [151]. The most common complementary hypotheses are the water
substitution model [152] and the glassy state model [152, 153]. The water
substitution model suggests the stabilization of antibodies via the formation
of hydrogen bonds with free hydroxyl-groups of the trehalose for example.
The glassy state model suggests the formation of a glass in which the proteins
are immobilized and thereby have their reaction kinetics of degradation and
denaturation highly retarded.
We used a volume of 0.5 µL and a concentration of 125 µg mL−1 dAbs in
60 mM trehalose and 20 mg mL−1 phenylalanine to ensure that dAbs would
be present at least in a 10 fold excess of CRP at a high concentration range
in clinical samples without using too a large microfluidic volume element of
the CS. Key steps for the deposition of the dAbs were to pipet the dAbs
solution into a main pad of each CS, freeze the chip and the reagents, and
then freeze-dry the chip and reagents overnight.
Figure 7.3a shows a lyophilisate of the dAb solution, which was frozen
at -18 ◦C. The lyophilisate is not distributed equally in the cross section
of the channel. Freeze-concentration occurred while the liquid was beeing
frozen [154, 155]. Approximately one quarter of the cross section of the mi-
crochannel is not filled with the freeze-dried material. Thus reconstitution
of the dAbs suffers from the entrapment of numerous gas bubbles. Lower-
ing the temperature to -196 ◦C increases the speed of freezing the reagents
and results in a finely structured lyophilisate, Fig. 7.3b. The small pore size
of the lyophilisate results in general in a slow drying process [148] but be-
cause of to the large surface-to-volume ratio of the small quantities and the
overnight drying, no difference was observed. The micrographs in Fig. 7.3c
and d show the redissolution and reconstitution of a lyophilisate in human
serum. This lyophilisate was prepared using a 150 nL solution of dAbs. The
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Figure 7.4. Time dependence of the relative concentration of labeled dAbs measured at the
entrance of the 20 µm deep reaction chamber of a CS. The three intensity series shown in
the graph correspond to volumes of freeze-dried detection antibody of 0.15 µL in a 30 µm
deep reconstitution chamber (f), 0.15 µL and 0.5 µL in a 180 µm deep reconstitution
chamber (`, a), which were redissolved and reconstituted in human serum. The optical
micrographs show the fluorescence intensity corresponding to dissolved dAbs (f) flowing
in the reaction chamber. The exposure time was 50 ms.
dAbs in Fig. 7.3c are almost completely wetted after 8.25 min and partially
redissolved. Some fragments of the dAb-phenylalanine-trehalose complex are
visible in the image, and the filling front moves at a rate of approximately
0.15 mm s−1. The filling front accelerates to ∼0.5 mm s−1 as soon as it reaches
the end of the lyophilisate. All fragments are dissolved, and the dAbs are re-
constituted in ∼50 nL of human serum at a concentration of ∼375 µg mL−1
45 s later, Fig. 7.3d. For the highest concentration of 3 µg mL−1 CRP used
here, dAbs were >100× in excess. During and shortly after the reconstitu-
tion step, dAbs bind to analytes present in the sample and the analyte-dAb
complexes proceed to the reaction chamber. Typically, solutions of 0.15 µL
(0.5 µL) of dAbs that were put into 180 µm deep and 2 µL large reconstitution
chambers reconstituted in human serum in a volume of 0.3 µL (1 µL).
The flow rate and volume of solution containing the dAb-analyte complexes
define the incubation time for capturing the complexes in the reaction cham-
ber. We therefore monitored the fluorescence intensity of a solution of re-
constituted dAbs passing at the entrance of the reaction chamber, Fig. 7.4.
Timing of the measurements started when the solution entered the reaction
chamber. In a first experiment, dAbs were deposited on the CS using a volume
of 0.15 µL of dAb solution and a 30 µm deep reconstitution chamber. The flu-
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orescence intensity corresponding to the dissolved dAbs decayed to less than
5 % of the initial intensity after the serum had been flowing for 600 s. Increas-
ing the depth of the reconstitution chamber to 180 µm significantly reduced
its hydraulic resistance and accelerated the flow of solution of dAbs at the
entrance of the reaction chamber. In this case, dAbs were reconstituted in a
larger volume of human serum. The fluorescence intensity corresponding to
dAbs passing at the entrance of the chamber initially decayed to below 10 %
of the maximum intensity in 30 s when 0.15 µL of solution of dAbs were used.
The fluorescence intensity decreased slowly to ∼2 % after 1000 s. Depositing
0.5 µL of dAbs in a similar reconstitution chamber significantly increased the
time needed to pass the dAbs through the reaction chamber: the fluorescence
diminished to 25 % of the maximum intensity in 30 s but remained as high as
14 % after 1000 s.
7.4.2. Functionality of the reconstituted detection
antibodies
The experiments described above show that reconstitution chambers and vol-
umes of dAbs can be varied to obtain a short or long-lasting flow of dAb-
analyte complexes through the reaction chamber. The next experiments focus
on one-step assays for CRP in which 2 µL and 0.15 µL large reconstitution
chambers have been used. In both cases, the depth of these chambers was
180 µm, and 0.15 µL of solution of dAbs was deposited and freeze-dried in
these chambers. The 0.15 µL reconstitution chambers essentially correspond
to the flow resistor and connecting channel placed between loading pad and
reaction chamber. CSs having such reconstitution chambers were directly de-
signed to hold 0.15 µL of dAbs solution and were not appended to an overflow
or secondary pad.
CRP-free human serum that was spiked with CRP (1 and 3 µg mL−1) was
directly loaded into the loading pad of these CSs. The transparency and low
autofluorescence of PDMS for the excitation and emission wavelengths used
for Alexa-647 allow the fluorescence signals to be measured over the capture
areas through the PDMS substrate. Fig. 7.5 shows the surface-bound and free
analyte-dAb complexes in the reaction chambers 10 and 25 min after loading
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Figure 7.5. Optical fluorescence micrographs of the reaction chamber of a one-step chip in
which a CRP immunoassay was performed. Capture antibodies were patterned on PDMS as
three vertical lines, indicated by dashed lines in (a), and crossed horizontally by six reaction
chambers in which the CRP-dAbs complexes were flowing. The six lines had alternating
concentration of 3 and 1 µg mL−1 CRP. Imaging the reaction chamber (a) 10 min and (b)
25 min after the sample was injected into the loading pad of the CSs illustrates how signal
originates in the areas of PDMS having cAbs. The exposure time was 50 ms.
the samples. Human serum reached the reaction chambers of CSs 3 and 4,
which had 0.15 µL reconstitution chambers, after a few seconds, whereas it
took approximately 8 min for the other CSs. Within 10 min, the binding re-
action was completed and a larger fraction of unbound dAbs had been washed
out of the reaction chamber. Both analyte concentrations of 1 and 3 µg mL−1
could be detected. The incubation time in reaction chambers 1, 2, 5 and 6 was
2 min and only the high concentration of CRP could be detected within 10 min
of loading the sample. In these CSs, the background signal from unbound
dAbs in the reaction chamber was still high, but 15 min later the binding re-
action had proceeded and concentration of unbound dAbs had decayed such
that also the concentration of 1 µg mL−1 could be detected, Fig. 7.3b.
These results suggest that for the concentrations used here a small recon-
stitution chamber and a high flow rate provide faster results, mainly because
the analyte needs less time to reach the reaction chamber where it is captured.
Nevertheless, for smaller concentrations that required longer incubation
times, the CSs having larger reconstitution chambers and slow flow rates
might be better.
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7.5. Conclusions
CSs enabling one-step immunoassays reduce the handling overhead of the end-
user from several pipetting step to a single one. Due to the small footprint
of these CSs, several CSs might be integrated one a single chip to perform
different assays in parallel. Multiple CSs can in principle be connected to
one loading pad and be linked to various reconstitution chambers, the ge-
ometries of which can be used to optimize the time needed for reconstituting
the dAbs and binding dAbs to analytes for a given concentration of analyte.
Alternatively, different types of dAbs can be positioned on independent flow
paths for performing multiplexed assays and for minimizing the risk of cross
reactivity between dAbs and cAbs. Besides performing independent assays
in parallel CSs, several assays may be performed in one CS exposing ana-
lytes to different, patterned cAbs. Pipetting robots or inkjet printers, which
are able to dose small volumes of solution of dAbs into reconstitution cham-
bers, should prove valuable for preparing CSs for fast analysis. The work
presented here suggests that the performance characteristics of CSs that we
previously reported, i.e., small volume of samples and reagents used, highly
integrated signals, multiplexed and fast assays, can also be achieved with
one-step immunoassays.
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Capillary Systems
Autonomous capillary systems (CSs), which are microfluidics inside which
liquids move owing to capillary forces, can in principle bring the high-
performances of microfluidic-based analytical devices to near patient and en-
vironmental testing applications. In this chapter,1 we show how wettable
capillary valves can enhance CSs with novel functionalities, such as delay-
ing and stopping liquids in microchannels. The valves employ an abruptly
changing geometry of the flow path to delay a moving liquid filling front in a
wettable microchannel. We show how to combine delay valves with capillary
pumps, prevent shortcuts of liquid along the corners of microfluidic channels,
stop liquids filling microchannels from a few seconds to over 30 min, trigger
valves using two liquid fronts merging, and time a liquid using parallel mi-
crofluidic paths converging to a trigger valve. All together, these concepts
should add functionality to passive microfluidics without departing from their
initial simplicity of use.
8.1. Introduction
Microfluidics have become increasingly used as high-end bio-analytical re-
search platforms [156, 157, 158], portable diagnostic devices [137], and in
many other applications [159, 160]. In general, microfluidics tend to be com-
plex compared to non-miniaturized bio-analytical instruments and they in-
corporate functional elements such as pumps, flow resistances, and valves for
controlling the flow of liquid. We have developed microfluidic autonomous
1M. Zimmermann, P. Hunziker and E. Delamarche, Valves for autonomous capillary sys-
tems, first published in Microfluidics and Nanofluidics, 5, 395–402, 2008.
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capillary systems (CSs) for performing miniaturised surface immunoassays
for both research and diagnostic applications [33, 49]. A CS comprises at
least a loading pad, a reaction chamber and a capillary pump, wherein liquids
move owing to capillary forces. We recently reported the concept of advanced
capillary pumps for encoding the displacement of defined volumes of liquids
with various flow rates in CSs for optimising the individual steps of an im-
munoassay, Chapter 5. In this chapter, we show how to enhance CSs with
more functionalities and valve-based actuation principles focusing on passive
valves for the control of liquids filling wettable CSs.
Valves are functional elements that are used to control the flow of a liquid.
A large number of different valves are commonly used in microfluidics [161]
and they are either actuated or non-actuated. Actuated valves usually have
moving parts and use electrostatic, electromagnetic, pneumatic, hydraulic or
thermal power to open or close [161]. These valves are most suitable for re-
peated dosing of the same liquid, controlling pressurised liquids, or for pump-
ing liquids [51]. Typically non-actuated valves having moving parts cannot
be opened or closed without changing the geometry of flow paths such as
with check valves, pressure control valves or flap valves. The most interesting
valves for combination with CSs are non-actuated valves that have no moving
parts such as hydrophobic valves [20, 162], diffuser valves [163], phase change
valves [117], and capillary valves [164, 165, 166, 167, 168], for example. These
valves are for single use: they influence how a liquid fills the region of the
valve but not how a liquid afterward flows through the valve. Capillary valves
can, in principle, withstand pressures in the order of 10 kPa [164, 169]. Melin
et al. have demonstrated wettable capillary valves for fluidic AND-gates, but
suction at the valve outlet had to be applied in order to release the valve
after the valve inlets were filled [170]. Passive microfluidic logic gates can
also be based on the surface tension of bubbles moving in a liquid [171] or
liquid droplets [172]. Actuated valves that have no moving parts such as
electrowetting-based valves [173] might also be integrated in CSs, but require
additional fabrication steps and electric circuits to operate the valve which
might be costly for ultimately disposable CSs.
The passive valves used in this paper, referred to as “valves”, are non-
actuated, do not have moving parts, but instead capillary forces propel or stop
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liquids filling these valves. These valves can be integrated seamlessly into CSs
and combined with different capillary pumps. A liquid pipetted into a loading
pad of a CS typically flows into the CS until the loading pad becomes empty
or the CS becomes filled [33]. Sequential pipetting of multiple reagents allows
to perform surface immunoassays in such CSs [34, 35]: different geometries
in a CS can tailor the flow rate of the liquid to optimise the conditions for
the different steps of the immunoassay, Chapter 5, but realizing a stop-and-
go flow is challenging. We present implementations of valves enabling such
functionalities.
8.2. Principle
The capillary pressure propelling liquids in wettable CSs originates from the
contact angle of liquids to the surface of CSs and the curvature of the meniscus
at the liquid-solid-gas interface (filling front) of the liquids in CSs. Valves alter
the curvature of the meniscus and in doing so the capillary pressure in the
liquid. The filling front can slow down or even stop depending on how strong
the meniscus is varied. The pressure barrier in such valves can be estimated
based on the total interfacial energy of the liquid-solid-gas interface system.
Energy changes at the interface modulate the capillary pressure and thus the
filling rate of a liquid in valves. The capillary pressure P in a liquid flowing
in a CS is [164]
P = −δET
δVl
= γla(cos Θc
δAsl
δVl
− δAla
δVl
) (8.1)
with the total interfacial energy ET of the capillary system, the volume of
liquid Vl in the CS, surface tension γla and the area Ala of the liquid-air inter-
face, contact angle Θc of the liquid with the walls of the CS, and the wetted
surface area Asl of the CS. The curvature of the meniscus in a straight chan-
nel is α = pi2 − Θc. At an abrupt enlargement having an angle β between
the old and new direction of the microchannel wall, the meniscus changes
its curvature in order to achieve the equilibrium contact angle. The curva-
ture disappears for β = pi2 − Θc = α and the capillary pressure drops to
P = 0. For larger β the curvature becomes negative and the sign of P changes.
The pressure barrier ∆P for a 2-dimensional valve (depth  width) can be
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calculated to [164]
∆P = 2γla
w
 cos Θc − αsinα sin β
cos β + sinβsinα
(
α
sinα − cosα
)
 (8.2)
with the width w of the meniscus in the valve. Using this equation Man et al.
determined the pressure barrier ∆P to be in the order of ∼10 kPa for water
(w = 5 µm,Θc = 20◦, β = 90◦) [164].
8.3. Experimental
The valves were fabricated in silicon using photolithography and dry etching.
A photoresist was exposed through photoplotted polymer masks (Selba S.A.,
Versoix, Switzerland) with a resolution of 25400 dpi (minimum feature size
∼10 µm) and laser written soda lime chrome masks (Delta Mask V.O.F.,
Enschede, Netherlands) with a minimum feature size of 1.5 µm. The polymer
masks were used for delay valves and chrome masks for stop valves. A deep
reactive ion etcher (STS ICP, Surface Technology Systems plc. Newport,
U.K.) was used to etch the valves 30 and 60 µm deep in silicon. After removal
of the photoresist, the wafers were coated with Ti (10 nm) and Au (150 nm),
and then diced to produce individual chips having each 11–24 valves connected
with loading pads large enough for pipetting.
Before testing valves on a chip, the Au surface of the chip was cleaned in
a UV-ozone chamber (UV-Ozone Photoreactor PR-100, Ultra-Violet Prod-
ucts, Upland, CA) for at least 20 min after the lamps had warmed up. The
chip was then immersed for 2 min in a 2 mM ethanolic solution of thiolated
poly(ethylene glycol) (HS-PEG 12750-4, Rapp Polymere, Tübingen, Ger-
many) to make the Au surface hydrophilic. The chips were then rinsed with
ethanol and blown dry under a stream of N2. The resulting Au surface had an
advancing contact angle of 40◦ with deionised water, which was coloured with
a food colorant (Werna W. Schweizer AG, Wollerau, Switzerland). A 1–2 mm
thick layer of cured PDMS (Sylgard-184, Dow Corning, Midland, MI) was
used to seal the valves.
The valves were tested within 30 to 90 min after derivatization of their
surface and sealing with PDMS. Coloured deionised water and coloured human
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Figure 8.1. Optical micrographs showing how a liquid arriving at the end of a capillary
pump can be collected into one output microchannel. (a) The merging of smaller channels
into larger ones defines delay valves, the purpose of which is to gradually collect a liquid
at the end of a pump. (b) Adding a resistance (outlined by the dashed rectangle) further
reduces the risks of having liquids wetting walls and short cutting programmed microfluidic
paths.
serum were used as liquids in this chapter. To prevent evaporation of liquid
from the loading pads, the chips with the sealed valves were placed in a
humidified chamber. The chamber was briefly opened to pipette liquid into
the loading pads. The performance of the valves was determined based on the
time until the valve released the liquid. The filling of liquids in the valves was
observed using a stereomicroscope (MZ16, Leica) and a microscope having
a 10× objective (Eclipse 90i, Nikon) equipped with digital photo and video
cameras (DCR-SR100E, Sony and DXM 1200C, Nikon).
8.4. Results and Discussion
The three functionalities that we want to integrate into CSs using valves are
preventing shortcut of liquids along the edges of microfluidic structures and at
the end of capillary pumps in particular, delaying a filling front, and stopping
a flow in wettable microfluidic elements.
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8.4.1. Delay valves
Fig. 8.1 shows valves for merging a wide filling front of liquid exiting multiple
microchannels into a single microchannel. Such delay valves retard one of
at least two filling fronts by increasing the size of the meniscus of the filling
front and thereby reducing its capillary pressure. A delay valve changes the
ratio of flow rates of two parallel flow paths. The velocity of a filling front
in a wide microchannel is lower than a filling front moving in a narrow mi-
crochannel. The menisci of the filling fronts in Fig. 8.1a move from a region of
high capillary pressure (width of microchannel 80 µm) into regions of reduced
capillary pressure (width of microchannel 90 and 130 µm). A single meniscus
proceeding through one of the delay valves gets retarded in its progression
until it merges with an adjacent filling front. Delay valves can be added in
a serial and parallel configuration to occupy a small footprint as shown in
Fig. 8.1. In some cases, when microchannels have highly wettable surfaces,
very smooth corners, or the outlet channel is very narrow, liquid might flow
along the corners of the microstructures more easily. In this case, delay valves
can be supplemented by increasing the roughness of the structures using a
lower resolution microfabrication process (e.g. polymeric photomasks) or by
adding structures having a large flow resistance. In Fig. 8.1b, a flow resistance
having 4-mm-long microchannels and a small total dead volume reduces the
chance of a liquid to shortcut the delay valves.
The same principle of delaying filling fronts can also be used for sequentially
filling parallel microfluidic elements, Fig. 8.2. The six rhombohedric elements
shown in the figure form a capillary pump and are placed above and below a
main inlet. The elements are numbered based on the filling sequence. Each
element is connected by a 30 µm wide microchannel to the 60 µm wide main
inlet at an angle of 45◦. The elements themselves comprise a network of 30 µm
wide parallel microchannels also connected at angles of 45◦. The liquid front
moves forward in the main inlet until it reaches a zone comprising the inlet for
an element and a delay valve (see inset in Fig. 8.2). The delay valves ensure
that each element fills entirely before the liquid moves further in the main
inlet and fills the next element. A supplementary video [174] exemplifies how
a liquid fills the elements one after each other in a highly controlled manner.
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Figure 8.2. Optical micrograph of an assembly of delay valves forming a capillary pump.
A liquid entering the pump by the inlet microchannel on the left will sequentially fill regions
(1), delineated by the dashed rhombus, to (6). Each region can have a specific pumping
power and volume capacity and a liquid filling one region is prevented from proceeding to
the next region by a delay valve (see inset). The filling of such a pump can be seen in a
supporting real time video [174].
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This concept is important for capillary-based microfluidics because a filling
element can impose specific filling conditions (volume and flow rate) until it
becomes filled and is bypassed by the main inlet. As a result, filled elements do
not add hydraulic resistance to the CS. Using this principle, a large capillary
pump can have specific elements and can dictate the duration and volume used
for the individual steps of a biological assay even if the assay necessitates a
large number of incubation and rinsing steps. As shown above, delay valves
can significantly slow down one filling front by placing it into competition
with a second filling front, which is moving in a zone of comparatively higher
capillary pressure. We discuss next how the inner geometry of microchannels
can be changed to stop a filling front.
8.4.2. Stop valves
The principle of a stop valve is to eliminate the curvature of a meniscus of a
filling front so that the capillary pressure P = 0. This is done by reducing
the width of a microfluidic path using a restriction and enlarging it abruptly,
Fig. 8.3a, similarly to the end of a glass capillary. In the region of enlargement,
the microchannel wall changes its direction by the angle β. The liquid follows
the changed direction of the microchannel wall, trying to keep its typical
contact angle to the microchannel wall. If β ≥ pi2 − Θc the meniscus flattens
or inverts its curvature and the filling front is pinned.
We have implemented a number of stop valves in silicon having different
angles at the abrupt enlargement and also two different widths of the re-
striction, Fig. 8.3b. Ideally, the abrupt enlargement should occur on all 4
walls of a microchannel. This would require a complex fabrication process
based on multilayer lithography or rapid prototyping. A large aspect-ratio
(depth/width) of ∼10 at the abrupt enlargement can be considered as a sim-
plified 2-dimensional system in which the influence of the bottom and top
channel walls on the liquid-solid-air interface system of the meniscus at the
filling front is negligible.15 Various types of stop valves, having such aspect-
ratios at a restriction, were designed in microchannels and tested. In Fig. 8.3b,
all microchannels are filled with black coloured water and the valves in mi-
crochannels 1, 2 and 5 stopped the liquid for at least a few seconds at the
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Figure 8.3. Principle and implementation of stop valves. (a) A restriction in a microchan-
nel having an abrupt enlargement is filled with liquid. The meniscus at the filling front
moves with a steady contact angle to the microchannel wall. At the abrupt enlargement
the contact angles change and the meniscus flattens and stops. (b) Optical micrograph
showing 30 µm wide wettable microchannels each having two stop valves in series. The mi-
crochannels are covered with PDMS. Microchannel 1, 2 and 5 are filled with black coloured
water up to the first stop valve.
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first stop valve. The valves in these microchannels were the ones having the
largest angles and smallest widths at the abrupt enlargement. These stop
valves were selected as the most promising ones for designing trigger valves.
8.4.3. Trigger valves
Stop valves can be assembled to form trigger valves where at least two liquids
must meet in the valve to trigger it and move forward in a common outlet.
Trigger valves can encode logical functions in CSs. Figure 8.4 shows trigger
valves each composed of two equivalent stop valves mirroring each other. The
two flow paths meet at different angles of 20◦ and 90◦. Therefore, the angles
β of the merged filling fronts are different, which influences the triggering
function of the valve. The spacing of the two stop valves reduces the risk of
liquid leaking from an already filled stop valve into the neighbouring empty
stop valve. The high fabrication accuracy, the sharp vertical edges, and narrow
restrictions at the abrupt enlargement, Fig. 8.4a, are important in order to
stop the filling front at an accurate position. We have implemented 12 different
types of trigger valves and tested their functionality with coloured water.
Fig. 8.4b shows the 4 best working types of valves. These valves were able
to retain liquid filled in one inlet for 15 min on average but the liquid was
occasionally not retained at all, maybe owing to imperfect microfabrication of
the valve or chemical functionalisation of its surface. Valves stable for 30 min
had their second inlet filled with coloured water to assess their triggering
functionality. In some cases triggering failed owing to a separation distance
of the adjacent filling fronts that was too large. An asymmetric design of the
trigger valve solves this problem by making it easier for the liquid to pass by
the valve in the second inlet.
Trigger valves, in which the first inlet has a stop valve and the second inlet
has a flow resistance, are shown in Fig. 8.5. The flow resistances designed
here lead to equal flow from each inlet once the trigger valve is actuated
but asymmetric flow rates can also be programmed. Six types of trigger
valves were tested. In view of using CSs for rapid in vitro diagnostics, trigger
valves were tested using coloured human serum. Serum has similar or slightly
smaller surface tension, [175] similar viscosity, and similar contact angles on
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Figure 8.4. Examples of trigger valves microfabricated in Si. (a) These SEM images show
trigger valves composed of two symmetric inlets, which meet at stop valves, and of one
outlet channel. (b) Optical micrograph of trigger valves having different types of stop
valves and having each an inlet filled with water coloured in green. The filling of the empty
inlet can be seen in a supporting real time video [174].
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Figure 8.5. SEM images of asymmetric, 30 µm deep trigger valves microfabricated in Si.
These six types of valves differ in the opening width and the change of contact angle at
the restriction. From (a) to (f), narrow openings, a large change of contact angle and the
asymmetry improve the performance of the trigger valve.
the surfaces of CSs as water. The valves were evaluated by filling human
serum in the first inlet of trigger valves and monitored if the valves were able
to hold the liquid for 5 min and to be triggered, Table 8.1. We found that
triggering the valve by adding liquid in the second inlet was not an issue
but that the success rate of the experiments depended on the retention of
the serum for at least five minutes. Valves having a 7 µm wide and short
restriction, Fig. 8.5a and b, were less efficient in stopping the first incoming
liquid than valves having longer and 5 µm wide restrictions, Fig. 8.5b and c.
Valves having narrow, 5 µm wide restrictions and a large angle β performed
best. In 69 % and 85 % of the tests done with the valves shown in Fig. 8.5e and
f, human serum stopped for at least five minutes and proceeded satisfactorily
upon triggering of the valves. Reducing the width of the restrictions further
and increasing their depth might improve the performance of the valves.
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Type of Change of Width of Success
valve contact angle restriction rate
/◦ / µm /%
a 155 7 7.7
b 155 7 7.7
c 135 5 15.4
d 135 5 23.1
e 160 5 69.2
f 160 5 84.6
Table 8.1. Geometry and chance of stopping human serum for ≥ 5 min for six types of
trigger valves shown in Fig. 8.5.
100µm
Trigger
valve
To the first
valve inlet,
30 µm wide,
2.5 mm long
Inlet
splits
100 µm
Common
inlet
To the second
valve inlet,
10 µm wide,
14 mm long
Figure 8.6. Optical micrographs of microfluidic timers. Trigger valves are assembled with
microchannels to have a common inlet that splits via a short and a long flow path to the
two inlets of the trigger valve. This microfluidic timer prevents the liquid from entering the
common outlet for 5 s.
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8.4.4. Microfluidic timers
Stopping a liquid in a CS for 5 minutes is a long time compared to the
timescale of biological assays previously performed in CSs. Fluorescence sand-
wich surface immunoassays performed using a CS have taken from a few min-
utes [35] up to 24 min [34] in the case of high sensitivity assays. Rinsing steps
can be as brief as a few seconds whereas incubation steps are on the order of
3 to 6 minutes. Delaying a liquid in a microfluidic structure for one minute
should be long enough for mixing liquids and reagents, dissolving reagents
dried in some microfluidic areas, stimulating cells in microfluidic chambers,
and metering a liquid. A microfluidic timer comprising a trigger valve con-
nected to microchannels having different lengths was realized, Fig. 8.6. The
timer has a common inlet that splits into a 30 µm wide and 2.5 mm long
microchannel and a 10 µm wide and 14 mm long microchannel. The shorter
microchannel is connected to the first inlet of the trigger valve and supplies
the liquid to the stopping element of the valve. The longer microchannel
draws liquid to the trigger element of the valve. A liquid entering the valve
will be delayed for a precise time until both filling fronts meet and trigger the
valve. In the microfluidic timer shown in Fig. 8.6, an aliquot of coloured water
needs 5 s to pass the timer. Both the width and length of the microchannel
connected to the second inlet of the trigger valve can be easily varied to yield
a timer having the desired time scale. Microfluidic timers can prevent a liquid
from filling the remainder of the CS for a certain time without substantially
increasing the overall hydraulic resistance of the CS.
8.5. Conclusions
Miniaturization and lab-on-a-chip concepts have brought impressive perfor-
mances in terms of short time to results, sensitivity, and parallelization to a
number of bio-analytical platforms. Commercialized point-of-care diagnostics
and analytical instruments for environmental testing have yet only marginally
benefited from miniaturization. The reasons might be the cost of miniatur-
ized bioanalytical devices, the degree of expertise needed from users, and
the fragility of these devices. By developing microfluidics for immunoassays
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wherein capillary forces draw liquids through functional microfluidic elements,
we hope to combine the performances of microfluidic-based systems with the
needs of end users for point-of-care applications. The passive valves shown
here enhance CSs with a range of functionalities such as safety features (delay
valves and flow resistances), timing features (delay and stop valves), and ba-
sic logical functions (trigger valves). The volume and time characteristics of
these elements range from nanolitres to picolitres of liquid and from seconds
to minutes, respectively. No complex microfabrication strategy is needed for
these valves and the designs reported here are in reach of conventional plas-
tic molding or embossing techniques used for mass fabrication of microfluidic
components. We therefore think that CSs incorporating valves represent a
promising tool for microfluidic-based bio-analytical tests to be used by non-
technical experts.
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9. Conclusions
Microfluidic CSs are a powerful technology for transporting minute volumes
of liquids through a micrometer-sized reaction chamber without any tubing or
electrical connections to peripheral instruments. Immunoassays in such CSs
can be optimized to obtain a maximum sensitivity, minimal sample consump-
tion or fast results by choosing an optimal flow rate as discussed in Chapter 2.
Flow rates can be programmed in CSs by selecting appropriate combinations
of flow resistors and capillary pumps. A solution for the problem of having a
sequence of fast and slow flow rates in the same CS has also been demonstrated
in Chapter 5.
An important criterion for medical diagnostic assays are fast results. CSs
are capable to generate large flow rates to capture enough analytes and gen-
erate a large fluorescence signal within a few minutes, Chapter 6. Stencils
minimize the effort for fabricating accurate and dense patterns of several cAbs
should allow performing of high-sensitive multiplexed surface immunoassays
efficiently in such CSs. We think that the open and flexible approach of
patterning cAbs and using the CSs will allow to develop a large variety of im-
munoassays in CSs. The approach of a one-step immunoassay in CSs greatly
simplifies performing of immunoassays and exemplifies the versatility of CSs,
Chapter 7. Such CSs for one-step immunoassays might not only be suited for
medical diagnostics, but also for other applications such as monitoring of food
and water quality, where immunoassays are preferably performed in the field
and fast results are desired.
Additional functionalities such as temperature control in the CSs might be
used to perform temperature sensitive assays, or to program the flow rate
at the time of use instead at the time of fabrication, Chapter 3. For assay
developments aiming at short development cycles this method might be a good
option. Other functions such as timing, metering, or triggering of liquids can
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be integrated directly in the flow paths of CSs using valves, Chapter 8. Such
valves enable digital microfluidic functions such as logic microfluidic AND-
gates, for instance.
We think that the methods and tools developed in this work are promis-
ing for being used by biological experts in life science research and are key
steps for developing one-step immunoassays in CSs for the ultimate benefit in
diagnostics at the point-of-care.
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A.1. Implementation of the model
The model was implemented using the method described in [43] and is divided
in two parts: the first part calculates the velocity vector field and the second
calculates the convection-diffusion-equation and the binding kinetics to the
concentration field.
The velocity vector field is calculated using the finite difference form of the
Navier-Stokes equation. The general impulse equations
∂u
∂t
+ ∂p
∂x
= 1
Re
(
∂2u
∂x2
+ ∂
2u
∂y2
)
− ∂ (u
2)
∂x
− ∂ (uv)
∂y
(A.1)
∂u
∂t
+ ∂p
∂y
= 1
Re
(
∂2v
∂x2
+ ∂
2v
∂y2
)
− ∂ (uv)
∂x
− ∂ (v
2)
∂y
(A.2)
are discretized on a regular staggered grid, Fig. A.1. To prevent numerical
oscillations the different variables for velocity in the x- and y-direction, u, v,
and the pressure P are localized at diverse positions on the grid cells. The
boundary conditions are “no-slip” (u = 0) on the channel walls, “inflow” (u =
const.) at the inlet and “outflow” (∂(u,v)
dn
= 0) at the channel end. Furthermore
we have to prevent stability problems occurring in discretized second-order
differential equations at convection-dominated flow conditions. For this, a
variety of different methods are described in literature. From these methods,
we chose the donor-cell scheme [176]:[
d (ku)
dx
]
= 12 δx (kr (ui + ui+1)− kl (ui−1 + ui)) +
1
2 δx (|kr| (ui − ui+1)− |kl| (ui−1 − ui)) , (A.3)
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Figure A.1. 2D staggered grid used to model the flow by diffusion and convection.
which has a good stability performance and combined it with the central
difference scheme [177]:[
du2
dx
]
i
= 1
δx
((
ui + ui+1
2
)2
−
(
ui−1 + ui
2
)2)
, (A.4)
which has a higher approximation performance than the donor-cell scheme.
Equations A.3 and A.4 are shown as a one-dimensional example. They are
averaged using a real parameter γ chosen from the interval [0, 1]:
γ ·Donor Cell + (1− γ) ·Central Difference . (A.5)
We have to introduce another stability condition for the time step to guar-
anty the stability of the numerical algorithm. We use a time-step control
which includes the Courant-Friedrichs-Levi conditions:
δt = τmin
Re
2
(
1
δx2
+ 1
δy2
)−1
,
δx
|umax| ,
δy
|vmax|
 , τ ∈]0, 1] . (A.6)
These conditions prevent volume elements of liquid from moving further than
one cell width, δx or δy, during the time δt.
The second part of the model applies only the convection-diffusion equa-
tion, Eqn. 2.3, and the binding kinetics, Eqn. 2.4, to the concentration field.
These equations have been discretized using the same models. The boundary
conditions for Eqn. 2.3 are a “constant concentration” at the inlet, “no flow”
across the channel wall, and a simple “outflow” condition. For boundary cells
next to the capture area, Eqn. 2.4 is linked to Eqn. 2.3 via the source term
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Figure A.2. Verification of the diffusion model using a slow convection in the x-direction.
The graphs show the concentration profile along the channel after 15 and 45 s, starting
from infinite source at inlet x = 0 µm into the initially empty channel. At flow velocities
≤ 0.07 µm s−1, diffusion predominates mass transport. Convection starts to have an effect
on the transport of analyte in the microchannel for a flow velocity of 0.7 µm s−1, and
substantially contributes to the transport for velocities > 7 µm s−1.
which can reduce or increase the analyte concentration in this boundary cell
depending on the saturation of the capture area and the binding constants.
A.2. Validation of the implemented numerical
model
Specific problems that can be described by analytical solutions are compared
with the simulated results. Figure A.2 shows the validation of the diffusion of
the analyte during the assay. In this case, the flow velocity of the liquid in the
microchannel is reduced to a minimal value to suppress convection. The mass
transport then results from diffusion. The analytical solution is given as a
reference. The correlation between the numerical and the analytical solutions
is excellent for the two graphs shown in Fig. A.2.
The flow velocity and the parabolic profile also have an important effect
on the mass transport of analyte within the microchannel. Figure A.3 gives
an example of the capabilities of the model to describe the flow in the mi-
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Figure A.3. Visualization of the self-established laminar flow profile for (a) a short zone
of flow development (at the inlet on the left-hand side) where the boundary conditions are
“constant inflow” (left), “no-slip” (top, bottom) and “outflow” (right), and (b) for a channel
having two obstacles.
crochannel. Figure A.4 shows the agreement between the analytical and the
numerical solution describing the self-established flow profile.
The correctness of the ligand-receptor binding model is shown in Fig. A.5.
No significant analyte exploitation occurs at high flow velocities. The curves
describing the saturation of the binding sites obtained with the numerical and
the analytical model are in agreement.
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Figure A.4. The resemblance of the flow profiles obtained with the analytical and numeri-
cal model validates the numerical model describing the velocity flow profile. The flow profile
here occurs at a x-position outside the flow development zone for a 50 µm deep channel.
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Figure A.5. Saturation of immobilized capture sites on a channel wall segment at 1 nM
analyte concentration. The binding reaction, represented by a ligand receptor model, is not
slowed down at flow velocities of 0.7 mm s−1. The lines are provided as guides to the eye.
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chips in plastics
Microfluidic capillary systems (CSs) can be used for patterning (bio-
)molecules on surfaces and to perform fluorescence assays with sub-microliter
volumes of sample and picomolar sensitivity. Typically, a CS comprises a
loading pad, a capillary retention valve, a microchannel wherein an assay can
be done, and a capillary pump. CSs can be cloned on a microfluidic chip for
performing independent assays in parallel. In our previous work, we utilized
CSs that were microfabricated in Si, coated with Au, and derivatized with
a wettable, thiolated poly(ethylene glycol). These chips fill spontaneously
owing to capillary forces. Here, we report two strategies to fabricate CSs in
plastic using hot embossing of cyclic olefin copolymer (COC). These strate-
gies might prove useful for the mass fabrication of CS regarding applications
in diagnostics, where disposable microfluidic chips are favoured. In addition,
COC is highly resistant to many organic solvents, non-permeable to water,
transparent, and has low auto-fluorescence.
B.1. Concept
Figure B.1 describes a first strategy for hot embossing COC using a Ni master,
which is obtained by electroplating Ni on a deep reactive ion etching (DRIE)-
micromachined Si wafer. With this strategy, it takes approximately one week
to fabricate the Ni master, and the cycle time to emboss one COC wafer is
only a few minutes. Figures B.1B-F show a profile and images of some areas
of a 30 µm deep embossed chip. Although these areas are very smooth, the
depth profile of the Si structures made the release of the COC chip after em-
bossing somewhat challenging: the DRIE process generated a slight undercut
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(∼0.5◦) of the Si structures which was conserved in the Ni master and inter-
locked with the COC replica. Since it can be difficult and time consuming
to adjust the profile of structures obtained using DRIE, we also used an al-
ternative method to optimize the profile of the master by fabricating it using
a high temperature resistant epoxy and SU-8 photoresist, Fig. B.2A. SU-8,
a negative resist, was here exposed from the backside and developed, which
resulted in SU-8 structures having ∼7◦ tilted sidewalls. After an intermedi-
ate replication step using PDMS, the tilted structures were replicated into
the epoxy master. Fabrication of an epoxy master required approximately
3 days. The profile and images of COC structures that have been fabricated
using this strategy show accurate COC replicas, Fig. B.2B-G. Similarly to Si
microfluidic chips, the COC chips were diced, coated with Au, and made wet-
table. These replicas could easily seal with PDMS and showed spontaneous
filling by capillarity, Fig. B.3.
B.2. Outlook
The replication of autonomous CSs in COC is promising for the miniatur-
ization of immunoassays using low cost, disposable microfluidic chips. In
addition, the SU-8 structures may be used to generate electroplated Ni mas-
ters, instead of epoxy masters, featuring high robustness and long lifetimes
necessary for hot embossing.
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Figure B.1. Hot embossing of 30 µm deep CSs in COC using a Nickel master fabricated
from a Si wafer template. (A) The Si master is structured using photolithography and
DRIE, and then coated with an Au seed layer for electroplating Ni. The Ni replica is
released by wet etching the Si wafer. (B) Depth profile of the 30 µm wide microchannels
of the 11 CSs composing one microfluidic chip. (C-F) SEM images of the 15 µm wide
capillary retention valves (C and D), microchannels (E), and capillary pumps (F) of the
CSs. A general difficulty in the preparation of electroplated masters for hot embossing is
found in the DRIE-derived profile of the Si master, which does not always have vertical
walls, but show a slight undercut of 0.5◦. During release of the embossed plastic wafer from
the Ni master, this can lead to minor imperfections such as the ∼2 µm high protrusions on
the edges of the channels (B), or missing posts in (F). The replicated structures otherwise
show smooth surfaces and good contour accuracy.
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Figure B.2. Hot embossing of 25 µm deep CSs in COC using an epoxy master fabricated
from a SU-8 structure. (A) A Cr layer on a transparent substrate is used to expose a
SU-8 layer from the backside, resulting in ∼7◦ slanted sidewalls. The SU-8 structure is
molded in PDMS and a high-temperature resistant aluminum-filled epoxy is then filled in
the PDMS cast. (B) Profile of 11 microchannels replicated in COC. (C) Photograph of a
hot embossed COC wafer and a single chip with 11 capillary systems (inset). (D-G) SEM
images of molded capillary retention valves (D, E), straight microchannels (F), and posts
in a capillary pump (G). The tilted walls of the master, especially visible in (E), enable an
accurate replication by facilitating release of the molded COC wafer from the master.
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 Assay Development Chip v.2 Datasheet 
 AD v.2 
 22.12.2006 
 
 
 
Assay Development v.2 Chip AD v.2.10 AD v.2.20 AD v.2.30 
Outer dimensions 22.5 × 27.5 × 0.5 [mm] 
Number of capillary systems 6 
Capacity of loading pad 1 µL 
Depth of loading pad 180 µm 
Volume of channel in front of reaction chambers 0.15 µL  
Volume of reaction chamber 2.7 nL 5.4 nL 8.1 nL 
Depth of reaction chamber  10 µm 20 µm 30 µm 
Width of reaction chamber 30 µm 
Length of reaction chamber 9 mm 
Volume of capillary pump 2 µL 
Depth of capillary pump 180 µm 
Vent at end of capillary pump x 
Pitch of loading pads 3.5 mm 
Pitch of reaction chambers 100 µm 
Bulk/Surface material Si/Au 
Surface monolayer HS-PEG (750 Da) 
Table 1. Dimensions. 
 
 
 
 
 
 
A. Block of PDMS (8 × 8 mm) sealing the reaction chambers of the capillary 
systems. Optional: The entire surface of the PDMS, which is in contact with the 
chip can be coated with capture antibodies in advance. 
 
B. Block of PDMS (24 × 20 mm) sealing the reaction chambers and the 
capillary pumps. The loading pads remain open for pipetting. No undesired 
evaporation of sample in the capillary pumps anymore. 
Figure 1. Assay development chips sealed with PDMS. 
 
 
 
 
Average Flow Rates 
in the Reaction 
Chambers 
Viscosity Setup  
as in 
AD v.2.20 AD v.2.30 
 [mPa s]  [nL s-1] CV (%) [nL s-1] CV (%) 
Water 1 Fig. 1B 1.85 4.7 4.16 4.8 
PBS + 1% BSA 1 Fig. 1B 1.85 5.0 3.96 3.4 
Solution of 20% hum. 
albumin 
4 Fig. 1A 0.51 12.0 1.51 11.9 
Table 2. Characteristic flow rates of liquids in the “Assay development v.2” chip. 
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